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ABSTRACT 
The present work includes distinct research projects having as common platform the 
design and synthesis of biologically active small molecules, useful as tools both for 
drug discovery and chemical biology studies. 
    The main project (Part I) focused on the identification of LDH-A inhibitors as hit 
candidates in the discovery of new anticancer agents. My work aimed to explore the 
chemical space around galloflavin (GF) by synthesizing a small library of analogs to 
perform  structure-activity relationships (SAR) studies. GF, LDH-A inhibitor previously 
identified and synthesized by our group, was not investigated in terms of SAR because 
of its poor chemical tractability. In the present work, a natural urolithin M6 (UM6) has 
been selected as a simplified structural analog of GF. It is endowed with improved 
physicochemical properties and it showed to reproduce GF’s biological behaviour on 
the enzyme and in cancer cells. An efficient fast and modular synthetic strategy has 
been developed to obtain UM6, which synthesis was not previously reported. This route 
gave an easy access to a series of structural analogs for SAR investigation, which 
allowed us to acquire a deeper knowledge about the key pharmacophore of UM6 and 
GF. 
    The second project (Part II), carried out at Oxford University under the supervision of 
Professor Angela Russell, aimed to use a chemical biology approach to develop a 
proneurogenic small molecule recently identified by the group (OX02672), into a 
fluorescent probe to assess its molecular interactions and localization in neural stem 
cells (NSCs). My work focused on the design and synthesis of alkyne-tagged 
derivatives of OX02672 for subsequent development into probes by “click” conjugation 
with azide-containing fluorophores. 
    The third part includes a side-project (Part III), carried out in collaboration with 
group of Professor Maria Laura Bolognesi. It focused on the design and synthesis of a 
series of multi-target-directed ligands (MTDLs) useful as potential hit candidates in the 
search for new drugs against Alzheimer’s disease (AD). Tacrine-resveratrol hybrid 
compounds, in which the structural features of the cholinesterase inhibitor drug tacrine 
are combined with the antioxidant anti-neuroinflammatory properties of resveratrol, 
have been designed and synthesized by using a fusing strategy. They showed interesting 
multi-target profile against target proteins involved in AD pathogenesis. 
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Part I 
IDENTIFICATION OF GALLOFLAVIN ANALOGS AS HUMAN LDH-
A INHIBITORS AND THEIR POTENTIAL AS ANTICANCER 
AGENTS 
 
1. Introduction 
1.1 Project overview 
Part I includes the main project of my PhD program, carried out under the supervision 
of Professor Marinella Roberti at the Department of Pharmacy and Biotechnology 
(UniBO), in collaboration with the group of Professor Giuseppina di Stefano (DIMES, 
UniBO). The present project focused on the design and synthesis of small molecules as 
inhibitors of LDH-A, currently under active investigation in the search for innovative 
anticancer combination therapies. 
 
1.2 Cancer metabolic reprogramming 
Reprogramming of energy metabolism has been recognized as one of the hallmarks of 
cancer.1  
The most relevant metabolic changes include enhanced glycolysis, increase in 
glutaminolytic flux, upregulation of amino acid and lipid metabolism, enhancement of 
mitochondrial biogenesis, induction of pentose phosphate pathway and macromolecule 
biosynthesis (Figure 1).2 These pathways are altered in order to provide cancer cells 
energy and precursors to support and enable rapid proliferation, continuous growth, 
survival, tissue invasion, metastasis and resistance to anti-cancer treatments.  
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Figure 1. Principal key metabolic changes in cancer.2 
 
In 1920’s it was recognised that energy metabolism is one of the first affected processes 
during neoplastic transformation3 but over the time, interest in metabolic properties of 
cancer began to decline with the view of cancer as a genetic disease.  
The metabolic reprogramming of cancer cells regained great attention in cancer research 
only in the last decade, when it was established that it is a direct result of alterations in 
oncogenes and oncosuppressors.4–6  
Thus many studies have recently focused on cancer cells altered metabolism with the 
aim to find new ways for effectively killing tumor cells.2,7,8   
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1.3 Glucose metabolism in normal and cancer cells 
One of the best characterized metabolic hallmark exhibited by tumor cells is the 
alteration in glucose utilization, with increased glycolysis and lactate production.9–11  
In all cells, glycolysis starts with the conversion of glucose in two molecules of 
pyruvate, the fate of which can be different, as it can be completely oxidized to CO2 in 
the mitochondrion or can be converted to lactate in the cytosol (Figure 2).12  
 
Figure 2. Glucose metabolism through glycolytic flux. 
 
    In normal cells (differentiated tissues), glycolysis is mainly coupled with oxidative 
phosphorylation (OXPHOS), thus pyruvate is completely oxidized to CO2 in the 
mithocondria via tricarboxylic acid cycle (TCA) and OXPHOS. Only under oxygen 
deprivation, OXPHOS cannot take place, thus pyruvate is converted into lactate 
(anaerobic glycolysis) in the cytosol (Figure 3A).10  
    In contrast, cancer cells metabolize glucose mainly through glycolysis with a minor 
use of the mitochondrial OXPHOS, regardless of the availability of oxygen (Figure 
3B). This alteration is known as “Warburg effect”, from the name of the scientist who 
first observed this phenomenon. 3,5,10,13–15 
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Figure 3. Schematic representation of glucose metabolism in differentiated tissues (A) and 
tumor/proliferative tissues (B).10 
 
An increased glycolytic flux, which is uncoupled from OXPHOS, is commonly 
observed in cancer cells and most of pyruvate is converted to lactate through lactate 
dehydrogenase (LDH). LDH is a key enzyme for cancer cells glycolysis because it 
reduces pyruvate to lactate with the coupled oxidation of NADH to NAD+, the 
regeneration of which is necessary for the continuation of glycolysis (See Figure 2). 
Importantly, while LDH plays a crucial role in tumor metabolism, it is not fundamental 
and not active in healthy cells, where glycolysis is normally coupled with OXPHOS.          
    Glycolysis only makes 2 ATP per glucose while mitochondrial respiration can 
produce up to 36 ATP for each glucose molecule catabolized; this raises the question 
why cancer cells select a less efficient metabolism in term of ATP production. 
The principal explanation is that enhanced glycolysis allows them the rapid production 
of many intermediates which can be used to generate building blocks (nucleotides, 
lipids, amino acids, and NADPH) for macromolecules biosynthesis required during 
cellular proliferation.16 Thus, contrary to normal cells, that aim to maximize ATP 
production converting all the glucose to CO2 via OXPHOS, cancer cells adopt an 
anabolic-type metabolism aimed at biomass construction.10 This metabolism is not 
exclusive of cancer cells, but is also observed in normal proliferative tissues and in 
many rapidly dividing embryonic tissues, confirming its role in supporting the large-
scale biosynthetic programs that are required for cell proliferation.17 
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Moreover, conversion of pyruvate to lactate could reduce reactive oxygen species’ 
(ROS) levels, avoiding generation of oxidative stress and promoting tumors’ 
survival.18,19  
    To compensate for the lower efficacy glycolytic ATP production and to sustain the 
greater demand for biomass, cancer cells increase the uptake of glucose through 
transmembrane glucose transporters (GLUTs).15,20,21 The increase in glucose uptake is a 
feature distinguishing tumor cells from normal cells and has been exploited in Positron 
Emission Tomography (PET) with the use of radiolabeled glucose analog, such as 18F-
deoxyglucose, as a tracer to visualize tumors.22 
It is worth noting that, even if glycolysis is enhanced and OXPHOS is reduced,   
mitochondria remain functional and some OXPHOS occurs in a large part of cancer 
cells, which use glycolysis to generate macromolecules but still derive a significant 
fraction of ATP from OXPHOS.23 However glycolysis becomes the primary source of 
ATP when the hypoxic microenvironment obstacles OXPHOS, such as in the hypo-
vascularized tumor regions. 
Lactate generated by LDH, secreted through monocarboxylate transporters, contributes 
to the development of extracellular acidosis that facilitates tumor invasiveness24,25 and it 
is also involved in the energy production. Indeed, lactate released as end product of 
glycolysis can fuel the oxidative metabolism of cancer cells growing in oxygenated 
microenvironment.7,26 
The reprogramming in glucose metabolism is mainly driven by the oncogenic signals 
that trigger cell proliferation, as it will be described in the next paragraph. 
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    1.3.1 Oncogenic mechanisms beyond tumor glucose metabolism 
The glycolytic phenotype exhibited from cancer cells has been shown to be associated 
with activation of oncogenes, signaling pathways and transcription factors, as well as 
the inactivation of tumor suppressors.15,21,27,28   
The elevated oncogenic activation, together with insufficient tumor suppressor control 
induce a transcriptional program that enables cancer cells to maintain a high glycolytic 
flux. 
The main oncogenes reported to induce increased glucose uptake and glycolysis are 
Ras, AKT, HIF-1, Myc, PIK3 (Figure 4).4,19  
 
 
 
Figure 4. Oncogenes and oncosuppressor implicating in glucose metabolic reprogramming.29 
 
Oncogene mutation of Ras activates mTOR via the PI3K-Akt-mTOR signaling 
pathway, and mTOR promotes glycolysis through inducing HIFs, particularly HIF-1.30–
32
  
HIF-1 is involved in the promotion of the glycolytic flux through overexpression of 
glucose transporters (GLUT1, GLUT3), hexokinases (HK1, HK2), 
phosphofructokinases 1(PFKFB3), aldolases (ALDA, ALDC), phosphoglycerate kinase 
(PGK1), enolase  (ENO1), pyruvate kinase M2 (PKM2), pyruvate dehydrogenase 
kinases  (PDK1, PDK2), lactate dehydrogenase A (LDH-A), and monocarboxylate 
transporter (MCT4).31,33 
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Myc directly activates glucose transporters and glycolytic enzymes, among which LDH-
A and PDK1.34 
Among tumor suppressors, p53 shows an inhibitory effect on glycolysis through 
different mechanisms, among which upregulation of TIGAR (TP53-inducible glycolysis 
and apoptosis regulator), that results in a decreased glycolytic flux35 and  stimulation of 
oxidative phosphorylation through upregulation of cytochrome c oxidase 2 (SCO2) 
(Figure 4).36  Thus, loss or deregulation of p53 shifts metabolism from mitochondrial 
respiration towards glycolysis. 
The upregulation of the majority of the glycolytic enzymes allows cancer cells to 
continuously drive glycolysis for supporting their rapid proliferation and accelerated 
biosynthesis (Figure 5). 
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Figure 5. Upregulated enzymes (in bold) in glycolysis of cancer cells.37 
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1.4 Targeting glycolytic enzymes as anticancer strategy  
The reprogrammed glucose metabolism can be exploited for therapeutic approaches to 
selectively target cancer cells.37  
Since the overexpression of most glycolytic enzymes is a common hallmark of tumors, 
inhibiting their altered activity may provide an effective mechanism by which to kill 
cancer cells.38–40  
The development of “antiglycolytic” anticancer agents in the search of new antitumor 
agents has been actively pursued and several small molecule inhibitors of many of the 
steps of the glycolytic pathway have been identified.41 
Currently, a number of drugs that target glucose transporter 1 (GLUT1)42,43, 
hexokinases (HK)44–48, phosphofructokinase 2 (isoform PFKFB3)49, pyruvate kinase 
isoform M2 (PKM2)50,51 and lactate dehydrogenase A (LDH-A)52 are under active 
investigation in preclinical or clinical studies, and representative examples are reported 
in Table 1.7 
 
Table 1. Glycolytic enzymes targeted in the development of new anticancer drugs. 
Target  Agent/s 
Development 
stage 
References 
GLUT1 WZB117, silibinin Preclinical studies 42,43 
Hexokinases 
2-deoxyglucose, 
lonidamine,  
3-bromopyruvic acid, 
methyl jasmonate 
Preclinical and 
clinical studies 
44-48 
 
Phospho-
fructokinase 2 
(PFKFB3) 
PFK158 Preclinical studies 49 
 
Pyruvate kinase M2  
(PKM2) 
TLN-232 Preclinical studies 50-51 
Lactate 
dehydrogenase 
(LDH-A) 
GNE-140, FX11, 
galloflavin 
Preclinical studies 52 
 
 
11 
 
    However, it should be recognised that there are potential obstacles in using glycolytic 
inhibitors for cancer treatments; indeed glycolytic enzymes are also necessary for 
glucose metabolism of healthy cells and their inhibition may be toxic especially for 
tissues that use glucose as main energy source. 
On the other hand, the enzyme LDH-A is poorly active in normal cells under sufficient 
oxygen supply. 
Therefore, among the glycolytic targets, LDH-A is considered the most promising and 
safe target to hinder cancer cell metabolism and growth without causing damage to 
normal tissues.53 
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1.5 The enzyme L-lactate dehydrogenase  
    1.5.1 Structure and function 
As we stated above, LDH catalyzes the reversible transformation of pyruvate to lactate, 
with the simultaneous interconversion of NADH to NAD+, (Figure 6) in the last step of 
glycolysis (See Figure 2). 
 
 
Figure 6. LDH enzymatic reaction. 
 
This enzymatic activity is conserved in organisms of the three domains of life54 because 
it can be an important source of ATP and NAD+ for living organisms during periods of 
anaerobiosis.  
Human LDH, mainly found in the cytosol, is a 140 kDa tetrameric enzyme (Figure 7A) 
composed of two major subunits, A (or M, predominately found in muscle) and B (or H, 
predominately found in hearth) that are encoded by ldh-a and ldh-b genes, respectively. 
An additional isoform LDH-C was identified in human testis and sperm.55 
The association of A and B subunits gives rise to five isoforms (Figure 7B): the 
homotetramer LDH-A, (or LDH-5) assembled from four A subunits, the homotetramer 
LDH-B, (or LDH-1) assembled from four B subunits, and three heterotetramers A3B1, 
A2B2 and B3A1.53 
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Figure 7. A) Tetrameric LDH structure (each subunit contains a NADH molecule;53 B) Schematic 
representation of LDH isoforms.52 
 
Crystal structures of the major isoforms in human, LDH-A and LDH-B, are reported;56 
LDH-A is found mainly in anaerobic tissues such as skeletal muscle and liver while 
LDH-B in aerobic tissues such as cardiac muscle. 
Since the A and B subunits show high amino acid sequence similarity (75%), the active 
sites is strictly preserved in the two isoforms LDH-A and LDH-B, whereas they differ 
in the kinetic properties.56 
    The isoform mainly involved in tumorigenesis is LDH-A, as it will described in the 
next paragraph, whereas the role and the implication of LDH-B in cancer cells have not 
yet been elucidated.57,58 
In normal cells under sufficient oxygen supply LDH-A is poorly active. It exerts its 
activity principally in anaerobic conditions: during intense work, for example in the 
overworking of skeletal muscle, glucose uptake and glycolytic flux massively increase 
and oxygen is in short supply. In this situation LDH-A reduces pyruvate to lactate 
regenerating NAD+ ensuring the maintanance of glycolysis and the resulting ATP 
production (lactic fermentation).53 
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    1.5.2 LDH-A in cancer cells 
LDH-A is fundamental to sustain the high glycolytic flux, thus allowing energy 
production in tumor cells which largely depend on glycolysis for their growth and 
survival. 
LDH-A-expression is constantly up-regulated in tumors and was found to correlate with 
tumor size and poor prognosis.4–6,59 
The overexpression of LDH-A, mainly driven by Myc and HIF-1, has been reported in 
highly glycolytic human cancers,60–65 and analysis of several tumors confirmed the 
higher concentration of LDH-A subunits compared to adjacent normal tissues.66 
Importantly, the high amount of lactic acid due to increased activity of LDH-A induces 
extracellular acidosis, that destroys the adjacent normal cell populations and promotes 
angiogenesis,  facilitating tumor invasion and metastasis.24,67  
Collectively, these data provided proof of concept that LDH-A is strictly involved in 
tumorigenesis and encouraged lots of studies on the benefic effects derived from its 
inhibition.  
 
 
    1.5.3 LDH-A as promising target for anticancer treatment 
The inhibition of LDH-A, by knockdown or small molecules, has demonstrated 
promising effects in preclinical investigations, which have confirmed the critical role of 
LDH-A in cancer cells and validated its inhibition as effective antitumor strategy, 
especially in combination with other therapeutic modalities. 
Silencing LDH-A expression was found to inhibit cancer cell proliferation and in vivo 
tumorigenesis in different tumor models68–73 and stimulate mitochondrial respiration 
with consequent ROS production that facilitates cell death.71 
As we previously stated, it is poorly active in normal cells, therefore its inhibition is 
considered a valid approach to selectively affect cancer cell metabolism. 
Moreover, evidences suggest LDH-A inhibition should be well tolerated by normal 
cells, since individuals with A or B subunit deficiency don’t accuse significant clinical 
symptoms74–78, in particular individual lacking A subunits complain muscle rigidity and 
myoglobinuria only after strenuous exercise.74,78  
15 
 
    Benefic effects derived from inhibition of LDH-A by small molecules are known for 
a long time with the LDH inhibitor oxamate, a structural isostere of pyruvate, which 
inhibits glycolysis of cancer cells cultured in vitro, even if only at high concentration. 79 
Furthermore, inhibition of LDH-A with oxamate was found to be a way to overcome the 
resistance of breast cancer cells to taxol80 and trastuzumab.81 In these works, resistant 
cells were shown to be more dependent on glycolysis for their survival, as consequence 
a combination treatment with the chemotherapeutic and LDH inhibitor resulted in a 
more pronounced therapeutic effect.   
    Overall, inhibition of LDH-A activity is considered a valid, selective and safe 
approach to damage cancer cells. Therefore many pharmaceutical industries and 
academia have recently focused their attention in the search of small molecule inhibitors 
of LDH-A, reported in several reviews.52,53,82   
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1.6 LDH-A inhibitors in the search for antitumor agents: an update 
Numerous strategies have been adopted in the discovery of LDH-A inhibitors: structure-
based virtual screening; high-throughput enzymatic screening of compound libraries; 
fragment-based approach; modification/optimisation of known inhibitors. 
These approaches allowed the development of many inhibitors, some of which showed 
high selectivity and potency in the nanomolar range against LDH-A; however very few 
of them resulted sufficient active in cell-based assays to progress toward clinical 
studies.83 
    Most of them share the presence of a carboxylic acid moiety, sometimes replaced 
with a bioisostere or masked as prodrug, that appears to be highly relevant in the 
binding with the active site of LDH-A together with a high number of hydrogen bond 
donors, which play a key role in the ligand-LDH binding.  
Indeed, the LDH-A reference inhibitor oxamic acid 1 establishes hydrogen-bonds with 
key catalytic residues in the active site (Arg-105, Arg-168, His-192 and Asp-165) and 
interacts with the side chain of Arg-168 through its carboxylate group as it is indicated 
through the analysis of the complex LDH-NADH-oxamate (Figure 8).  
 
 
Figure 8. Structure of LDH-A inhibitor oxamic acid 1 and its interaction with LDH-A. 
 
An overview of the main classes of LDH-A inhibitor identified so far is illustrated in 
Figure 9, and the most promising of them will be briefly described.  
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Figure 9. Overview of chemical classes of LDH-A inhibitors. 
 
• N-hydroxyindole scaffold-based inhibitors  
N-hydroxyindoles (NHIs) showed inhibitory activity in competition with 
both the cofactor NADH and the substrate pyruvate with IC50 in the low 
micromolar range against LDH-A.84–86   
SAR studies indicated on the “OH-COOH” motif the pharmacophore of 
this class, that partially resembles the structure of the natural substrates 
of LDH, i.e. an α-ketoacid (pyruvate) or α-hydroxyacid (lactate). The 
most active compounds, 2a-b, displayed a synergistic cytotoxic effect in 
combination with gemcitabine under hypoxic conditions and inhibited 
cell migration and invasion in pancreatic cancer cells.87 Glucose 
derivatives 3a-b displayed weaker inhibitory activity against LDH-A but 
they exhibited more efficacy in cell-based assays.85 
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• Chimeric (bifunctional)-type inhibitors 
Chimeric LDH-A inhibitors are bifunctional molecules in which two 
portions, one a substrate mimic and the other a cofactor mimic, are 
conjugated by a linker. Representative examples of this class are 
compounds 388 and 489, discovered through a fragment-based approach 
by AstraZeneca and  ARIAD Pharmaceuticals, respectively. They both 
showed high potency in enzymatic assays with inhibitory activity in the 
nanomolar range against LDH-A, but not optimal physicochemical 
properties, thus they require further optimization. 
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• Dihydropyrimidine- and pyrazine-based inhibitors 
By following a high-throughput screening approach, Genentech 
identified dihydropyrimidines 5a-e90 and pyrazines 6a-d91 as LDH-A 
inhibitors active in the micromolar range. Some of these derivatives 
exhibited potency in the high nanomolar range, but they require further 
optimization to improve cell membrane permeability and to obtain 
analogs with improved cellular activity. 
H
N
S
O
N
HN
S Cl
CN
O
OO
H2N
R1
R3
5
a: R1= R2= H
b: R1= Me, R2= H
c: R1= Et, R2= H
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• Dihydropyrone- and hydroxylactam-based inhibitors  
Dihydropyrone-based derivatives92 were identified by Genentech 
through high throughput screening (HTS), and after hit to lead 
optimisation, 7 resulted the most active compound against LDH-A (in 
the nanomolar range), but it showed weak activity in cell-based assays. 
In order to further investigate this class of compounds the dihydropyrone 
core was replaced with a hydroxylactam. Among the new 
hydroxylactam-based derivatives, 8 (GNE-140) was identified as potent 
enzymatic inhibitor of both LDH-A and LDH-B, possessing adequate 
pharmacokinetic properties that make it suitable for its use as an in vivo 
tool compound.93 Results on potency in cells, mechanism of action and 
tumor growth inhibitor have been recently reported.94 
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• Quinoline scaffold-based inhibitors 
Quinoline and quinolone derivatives (general structure 9 and 10, 
respectively) were identified as potential scaffold in the search for new 
LDH-A several decades ago.95,96 Recently, GSK reported potent 
quinoline-based LDH-A inhibitors, moderately selective for LDH-A over 
LDH-B.97 These molecules, particularly the most active compound 11, 
showed LDH-A inhibitory activity also in cultured cancer cells. 
However, their pharmacokinetic properties need to be improved for 
further in vivo studies.97,98 
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• Pyrazole-based inhibitors 
Very recently, Ganesha et al.99 reported the discovery and medicinal 
chemistry optimization of a novel series of pyrazole-based inhibitors of 
LDH-A. By using a quantitative HTS they identified the hit candidate 12; by 
structure-based design and optimization they developed compounds with 
more potent enzymatic activity. Compound  13 resulted one of the most 
active, exhibiting low nM inhibition of both LDH-A and LDH-B and 
inhibition of lactate production and glycolysis in MiaPaCa2 pancreatic 
cancer and A673 sarcoma cells at submicromolar concentration.99 
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• Polyphenolic-based inhibitors  
A representative compound of this class is gossypol, a natural polyphenol 
derived from the cotton plant. The most active enantiomer form, (R)-(-)-
gossypol 14, inhibits both LDH-A and LDH-B in micromolar range by 
competition with NADH, but it is not specific for this enzyme. It exhibits a 
broad spectrum of biological activities, such as antitumor, antioxidant, 
antiviral and antiparasitic,100,101 and it also causes unspecific toxicity mainly 
due to the presence of aldehyde and catechol groups which generate toxic 
metabolites.102–104 Nevertheless, (R)-(-)-gossypol entered clinical trials in 
combination with antitumor agents for the treatment of different tumors, 
with some studies terminated because of unacceptable toxicity and other are 
still ongoing. (clinicaltrials.gov)  
    In an attempt to develop less toxic and more selective inhibitor, several 
molecules structurally close to gossypol were synthesized, particularly 2,3-
dihydroxynaphthoic acid derivatives,105,106 initially designed as antimalarian 
agents.106 Among them, compound 15 (FX-11) resulted the most potent 
inhibitor and displayed also good selectivity for LDH-A isoform.64 It showed 
to reduce ATP and lactate production, induce oxidative stress and cell death 
in cultured cancer cells.64 However, further studies gave rise to suspicion 
that its effects could be not ascribed to LDH-A inhibition but to the reactive 
catechol group88,89 and it was never tested in clinical trials. 
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    Other polyphenolic compounds based on flavon structure were found to 
be potential anticancer agents due to their inhibitory activity against LDH-A 
such as the flavone morin 16107 and the flavon-like derivatives, 
epigallocatechin 17 and galloflavin 18. 
Epigallocatechin (17), naturally found in Spatholobus suberectus, inhibited 
both LDH-A activity and HIF-1 expression, showing significant inhibition of 
breast cancer growth; it is considered a lead compound for further 
investigation.108 
    Finally, galloflavin (GF, 18) is a derivative of gallic acid recently 
identified through a virtual screening campaign as LDH-A inhibitor by our 
group.109 GF was found to inhibit the enzymatic activity of purified LDH, by 
occupying the NADH site, and the lactate production in cultured cancer cells 
in the micromolar range. Many investigations on GF activity in different 
cancer cell lines and its mechanism of action were carried out.110–114 These 
studies confirmed GF antitumor effects and showed it is not harmful for 
mitochondrial respiration, suggesting tolerability for normal cell metabolism 
and thus encouraging the further exploration of this compound.  
Hence, the development of promising GF analogs is the aim of the present 
work, and is directly addressed in the next chapter (2. Aim of the work). 
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It is evident that very few LDH inhibitors have progressed to the preclinical stage and 
into clinical trials to date,83 often because of poor pharmacokinetic profile, particularly 
poor penetration inside cells with consequent lack of cellular activity. The improvement 
of drug-like properties is fundamental for their use as in vivo tool compounds and their 
further development.  
    It is worth noting that the discovery of selective LDH-A inhibitors proved to be very 
difficult because of the high structural homology in the active sites of A and B subunits. 
However, some of the most potent and cell-active compounds, such as 8 (GNE-140), 13 
and 18 (GF), are non-selective for LDH-A over LDH-B. 
Therefore, current efforts aim to the discovery of potent LDH inhibitors with good 
drug-like properties, not necessarily pursuing selectivity towards isoform LDH-A 
(“pan-LDH inhibitors”).93 
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2. Aim of the work  
Within a research project that aims to the development of new innovative anticancer 
agent targeting tumor metabolism, our group has been involved in the search for new 
LDH-A inhibitors, through a collaboration with Professor Recanatini’s and Professor Di 
Stefano’s groups. 
In these context, we recently discovered LDH-A inhibitor galloflavin (GF, 18)109 
(Figure 10a), which is now produced and sold by several suppliers. GF is considered as 
a reference compound among the anticancer glycolytic inhibitors since its antitumor 
effect has been well-established in several studies.110,112,114,115 Notably, some of them 
have suggested that inhibition of LDH is not the only bioactivity of GF. A 2D in-cell 
NMR metabolomics study recently revealed that GF affects other metabolic pathways, 
influencing pyruvate dehydrogenase kinase (PDK), alanine aminotransferase 1 (ALT1) 
and pyruvate dehydrogenase (PDH),  and suggesting that GF anticancer effects could be 
due to its multi-target effect rather than to specific inhibition of LDH.111 Fiume et al.113 
reported that GF hinders the interaction of LDH-A with ssDNA and inhibits RNA 
synthesis in cultured cancer cells, suggesting its antiproliferative activity can derive not 
only by blocking tumor glycolysis but also by RNA synthesis inhibition; furthermore, 
GF can be a useful tool to study the biological role of LDH-A binding to ssDNA. 
GF and oxamate were found to reverse the inflammation-induced effects in cancer cells 
in a recent study by Manerba et al.116 The same group reported that LDH-A inhibition 
by GF and oxamate led to decreased level and function of the major heat shock proteins 
involved in tumorigenesis suggesting a connection between LDH and heat shock 
response.117 These data confirmed the hypothesis that GF possess multiple biochemical 
properties and suggest that the polyphenolic structure could be an appropriate molecular 
scaffold to design compounds joining LDH inhibitory activity with other anticancer 
effects.117 
Therefore, the anticancer potential of GF is of great interest as well as its employment 
as tool to investigate the effects of LDH inhibition. 
    Galloflavin (GF, 18) is synthesized from gallic acid (GA) in a one-step 
dimerization/oxidation process mediated by NaOH109,118 (Figure 10a). It is a 
polyhydroxylated tricyclic compound, based on fusion of a isocoumarin and a pyrone 
core (Figure 10b). 
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Figure 10. a) Synthesis of GF; b) Molecular structure of isocoumarin and pyrone cores 
 
The calculated binding pose postulated in the initial study, as reported in Figure 11, 
suggested GF binds mainly to the enzyme by hydrogen bonds.109  
 
Figure 11. Galloflavin docking pose with human LDH-A, obtained by the VS procedure.109 
 
However, GF still requires an investigation in terms of Structure Activity Relationships 
(SAR). The SAR assessment is crucial for candidate hits, together with the 
improvement of the pharmacokinetic profile, to progress towards the hit to lead 
optimization phase in the drug discovery process.  
The present work aims to the disclosure of GF SAR, through the synthesis of a series of 
structural analogs, in order to gain a deeper knowledge on the effective key interactions 
involved in its binding to LDH.  
GF SAR assessment proved to be very challenging for two main reasons: first, its 
synthesis is not versatile and did not allow access to structural analogs; second, GF did 
not prove to be a practical starting point for the synthesis of analogs because of its poor 
solubility in common organic solvents and its fast degradation under both basic and 
acidic conditions. 
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Therefore, we undertook a rational design aimed to reproduce GF pharmacophore on 
simpler and synthetic accessibile scaffold, with improved physicochemical properties, 
which could allow us the synthesis of a series of derivatives, without having to deal 
with the poor chemical manipulability of the original molecule. 
We carried out a structural simplification of GF, taking into account three main aspects: 
1) elimination of the double pyrone sysyem (B and C rings, Figure 12a) that brings 
complexity and pose significant synthetic challenges; 2) keeping the same position and 
distance of the four hydroxyl groups, to best reproduce the H-bond fingerprint of GF, 
that is likely a key factor in GF binding to LDH; 3) retaining tricyclic skeleton, useful to 
mimic the origical structure. This process led to the identification of compound 19, 
known as urolithin M6 (UM6), by simply substituting the pyron ring C with a benzene 
ring. (Figure 12a). The overlap of GF and UM6 structures is illustrated in Figure 12b. 
 
 
 
Figure 12. a) Structural simplification of GF toward UM6; b) overlap of GF (blu)  and UM6 (yellow). 
 
Particularly, UM6 core is based on the same GF isocoumarin ring (blu, Figure 13), 
fused with a benzene (pink) in place of the pyrone (red), thus resulting in a 
benzo[c]chromenone core (Figure 13).  
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Figure 13. GF and UM6: core structure comparison. 
 
The benzo[c]chromenone scaffold (also called dibenzopyranone or  benzocoumarin) is 
found in many natural products and biologically active molecules, and is considered as 
a privileged structure, since it is of great importance as intermediate for the synthesis of 
various pharmaceutically interesting compounds.119–122  
In particular, UM6 is a tetrahydroxylated dibenzopyranone derivative that belongs to 
the urolithin family, a class of recurrent metabolites after the assumption of aliments 
rich in ellagitannins, such as pomegranates, berries, walnuts, almonds (Figure 14).123,124 
Their natural origin and common presence in gut microbiota suggested a promising 
safety profile for this class of compounds. Moreover, a number of beneficial properties 
and biological activities have been recently attributed to urolithins, such as 
antioxidant,125,126 anti-inflammatory,126–129 anticancer130–133 and antiglycation133 
activities. 
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Figure 14. Gut microbiota metabolism of ellagitannins and ellagic acid. 
 
    Since both its scaffold and OH substitution pattern is high similar to GF, we assumed 
that UM6 could maintain GF pharmacophore and mimic its LDH-A inhibitor activity 
and thus be useful as starting point for our investigations.    
It was characterised as an ellagitannin metabolite by Ito et al.134 and its production via 
biotechnological methods has been reported,135 while neither a biological study, nor 
chemical synthesis have been reported. 
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Therefore, the first step of the present project was the development of a synthesis for 
UM6 and a preliminary biological evaluation to assess if UM6 could be a GF 
biomimetic.136 
Some strategies were reported in the literature for the synthesis of other urolithins, as it 
is illustrated in Figure 15 and summarized below: 
1) copper catalyzed Hurtley reaction, that is described for synthesis of urolithins that 
possess one or two hydroxyl groups, such as Uro-A, Uro-B;125 however it presents 
issues of very low yields and it doesn’t seem much versatile; 
2) basic decarboxylative hydrolysis of ellagic acid (EA) permits to achieve urolithin M5 
according to literature, but no other urolithins have been obtained through this route;137 
3) inverse electron demand Diels–Alder reaction is reported for total synthesis of UM7; 
however it is highly substrate-dependent and expensive in terms of both starting 
materials and number of steps;138 
4) Esterification of 2-bromobenzoic acids followed by ring closure through Heck 
coupling is reported for Uro-D;139 however yields are usually poor and reaction times 
very long. 
 
Na
OH
 
Figure 15. Current methods for urolithins synthesis. 
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All these methods have some major drawbacks and above all, none of them seemed 
particularly attractive, since our purpose was to develop an efficient and versatile 
synthetic procedure that could allow a facile access not only to UM6 but also to the 
synthesis of future structural analogs for SAR investigations. 
Therefore we planned a new synthetic strategy, illustrated in Scheme 1, taking into 
account the use of protecting groups (PG) for the presence of four OH functionalities. 
The planned synthesis features the use of a methyl ester GA derivative, which is 
brominated, coupled with the opportune protected boronic acid and then idrolyzed to 
give the 2-arylbenzoic acid. This intermediate is then transformed into lactone through 
K2S2O8- (Route A) or NIS-mediated (Route B) C-H oxygenation and finally deprotected 
to achieve the desired UM6 (19). 
 
Scheme 1. Planned synthesis of UM6 
 
 
Different protecting groups were screened, and the methyl ether was selected as the best 
option as it resulted stable under the synthetic conditions. The optimized synthesis, 
shown in Scheme 2, started with initial NBS-mediated bromination of the commercially 
avail- able methyl-3,4,5-trimethoxybenzoate 20 to obtain the corresponding methyl-2-
bromo-3,4,5-trimethoxybenzoate 21. The subsequent Suzuki coupling with 4-
methoxyphenylboronic acid 22 with Pd(PPh3)4 and K3PO4 in DME in microwave 
heating for 1 hour (or in conventional heating 24h in a pressure tube) led to 
methyltetramethoxybiphenyl-2-carboxylate 23, which was subsequently hydrolyzed 
with NaOH to generate the free tetramethoxybiphenyl-2-carboxylic acid 24. Successive 
ring closure through C–H oxygenation was initially performed using  K2S2O8/AgNO3 
10% in 1/1 H2O/ CH3CN for 48 h at 60 °C, which led to the desired cyclized product 25 
with a non-optimal yield of 30% (Route A). To obtain a better yield, 2-arylbenzoic acid 
intermediate 24 was subjected to a radical oxidative lactonization mediated by N-
iodosuccinimide (NIS) (Route B).140 The reaction was carried out in 1,2-dichloroethane 
at 75 °C for 3 hours and afforded the desired cyclized compound 25 in a satisfactory 
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69% yield. The final deprotection in BBr3 led to the desired 19 in 58% yield, after 
purification by C18 flash silica gel. This synthetic route provided UM6 in 5 steps and 
27% overall yield. 136 
 
Scheme 2. Optimized UM6 synthesis 
 
 
    Preliminary biological evaluation revealed UM6 inhibited both the enzymatic activity 
of LDH-A and lactate production in cultured cancer cells at comparable levels to GF, 
confirming it can be considered a GF biomimetic and that it could be a suitable hit 
structure in the field of LDH-A inhibitors.136 
In view of this encouraging result, new UM6 analogs were designed to explore the SAR 
of this class of compounds and synthesized applying the efficient newly developed 
synthetic strategy. Indeed, a structural variability of analogs can easily be achieved with 
this procedure simply by using of different boronic acids as building blocks for the key 
Suzuki step. 
Initially, with the aim to evaluate the role of the hydroxyl group in the C ring and the 
influence of changes in the lipophilicity of the molecules we designed and synthesized 
the UM6 analogs 26-31 (Scheme 3). 
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Scheme 3. Synthesis of UM6 analogs 26-31 
 
Starting from methyl-2-bromo-3,4,5-trimethoxybenzoate 21, Suzuki coupling was 
performed with the differently substituted boronic acids 22a-f to give 
tetramethoxybiphenyl-2-carboxylate derivatives 23a-f. Suzuki couplings were 
performed in conventional heating in pressure tube instead of microwave heating 
conditions, because it allowed to scale up the reaction to ~1 gram. Biphenyl-2-
carboxylates 23a-f then hydrolysed to the corresponding biphenyl-2-carboxylic acids 
24a-f. Successive ring closure were performed using the more efficient procedure of 
NIS-mediated lactonisation to obtain the benzocoumarin derivatives 25a-f, which upon 
deprotection of the methoxyl groups gave the desired OH-free final compounds 26-30 
with yields comparable to UM6. Only in the case of benzocoumarin 25f the final 
demethylation didn’t proceed completely, giving the methoxyderivative 31 instead of 
the expected trihydroxylated derivative. Characterisation by 1H-NMR, 13C-NMR, 
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DEPT, HSQC, HMBC and NOESY experiments was performed in order to confirm the 
position of the methoxy function on the A ring. 
Notably, as it is illustrated in Scheme 4, cyclisation of the non-symmetrical biphenyl-2-
carboxylic acids 24c, 24d, could occur in 2’ or 6’ position leading to different products. 
In both cases we obtained only the compound derived from cyclisation in 2’ position 
(25c and 25d), as we confirmed by 1H-NMR spectra. 
 
Scheme 4. NIS-lactonization of non-symmetrical bifenyl-2-carboxylic acids 24c-24d 
 
 
    After investigating the importance of the substituents on the C ring of hit compound 
UM6, we directed our attention on the lacton moiety and designed compound 32 
(Figure 16), which differs from UM6 in the reverse position of lacton function in the B 
pyron ring. Notably, it can be also considered as a UM6 differently OH-substituted 
analog, as it could be appreciate by drawing the molecules in two different ways 
(Figure 16). 
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Figure 16. Derivative 32 (different way to representation) in comparison with UM6.  
 
The synthesis of compound 32 (Scheme 5) was performed starting from Suzuki 
coupling between the commercially available methyl 2-bromo-5-methoxybenzoate 21a 
and (2,3,4-trimethoxyphenyl)boronic acid 22g, and proceeded through the same steps 
previously described for the synthesis of UM6 and its analogs. 
 
Scheme 5. Synthesis of analog 32 
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Additionally, we designed and synthesized three UM6 analogs 33-35 (Figure 17) that 
share the same trihydroxylated ring A and the hydroxybenzene ring C, while they differ 
in the B portion as follow: i) lacking of B ring gives the lacton ring-opened analog 33; 
ii) carbonyl reduction of lactone ring gives analog 34; iii) substitution of B ring with 
benzene results in the phenanthrene derivative 35. 
 
 
Figure 17. Structural modification of UM6 towards other scaffolds. 
 
 
The synthesis of 33-35 has been planned starting from the intermediate 23 of UM6 
synthesis, which assumes a central role in the intersection between three different 
synthetic routes, as it is showed in Scheme 6. Derivative 33 was obtained through 
hydrolysis followed by demethylation. Analog 34 was planned through the route that 
led 23 to UM6 and reduction of the latter with NaBH4/BF3·Et2O; unfortunately this 
reaction didn’t work as expected and the compound was not obtained. Phenanthrene 
analog 35 was synthesized starting from conversion of 23 to aldehydes 36 (42% yield 
over two steps), which reacted in a Wittig fashion with 
(methoxymethyl)triphenylphosphonium chloride to afford the corresponding arylvinyl 
methyl ether 37 (56%). Bismuth-catalyzed cyclization-aromatization led to the protected 
phenanthrene 38 (65%), which was deprotected to obtain the final tetrahydroxy-
phenantherene analog 35 (86%) (Scheme 6).  
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Scheme 6. UM6 analogs with different scaffold  
 
    To further extend the applicability of our synthetic plan and to investigate the role of 
the trihydroxy-moiety in UM6 A ring, we then synthesized urolithin M7 (UM7), in 
which the 8,9,10-trihydroxy moiety is substituted with 8,10-dihydroxy moiety. (See 
Figure 14) 
Therefore the synthesis of UM7 (39, Scheme 7) started from methyl 2-bromo-3,5-
dimethoxybenzoate 21b and (4-methoxyphenyl)boronic acid 22 and followed the 
optimised procedure previously used for UM6 and analogs, leading to the product with 
a 20% overall yield. 
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Scheme 7. Synthesis of UM7 
 
 
UM7 synthesis has been previously reported in 2011 by Pottie et al.,138 however our 
strategy proved to be a faster and simpler alternative. Indeed, Reddy, M. D. et al.141 
recently reported a new UM7 synthesis taking into account our synthetic plan.   
    Additionally, to validate our synthetic strategy, and to compare it with the known 
methods for urolithins’ synthesis, we decided to explore the preparation of UM6 and 
UM7 through the Hurtley reaction (Scheme 8), which is reported to be a fast and 
effective method for dibenzopyranones synthesis.142 Thus, methyl ester derivatives 21, 
21b were hydrolysed to the correspondent acids 40, 40b, which were condensed with 
resorcinol 41 in a 4M NaOH solution with CuSO4 as catalyst to give the methylated 
benzocoumarins derivatives  42, 42b (14% and 3% of yield, respectively). Finally, 
demethylation of 42 led finally to UM6 (40%). Demethylation of 42b was not 
performed because of the too low amount of material obtained, but we can reasonably 
affirm that the reaction would give UM7 (Scheme 8). 
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Scheme 8. UM6 and UM7 synthesis through Hurtley reaction 
 
The major drawback of this synthesis is the very poor yield in the key step of 
benzocoumarin ring formation. However, since it is a very short procedure and the 
Hurtley reaction has been recently re-explored for the synthesis of some substituted 
benzocoumarins,142 we exploited it to obtain UM7-inspired analogs.  
   In particular, we designed and synthesized compound 43, that is the UM7 analog with 
the reverse lacton function (Figure 18) together with dibenzopyranone (46a-b, 43) and 
dibenzopyrane (47-49) derivatives as illustrated in Scheme 9. 
 
 
Figure 18. Derivative 43 (different way to representation) in comparison with UM7. 
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Commercially available 2-bromo-5-methoxybenzoic acid 44a, and 2-bromobenzoic acid 
44b were condensed with phloroglucinol 45 in a 4M NaOH solution and CuSO4 as 
catalyst to give dibenzopyranones 46a, 46b142 (68% and 83%, respectively). Methylated 
derivative 46a was subsequent deprotected to obtain compound 43 (34%). The 
dibenzopyranone compounds 46a, 46b and 43 were reduced with NaBH4/BF3·Et2O to 
the corresponding dibenzopyrane analogs 47, 48 and 49 (62%, 23% and 17 %, 
respectively) (Scheme 9). 
 
Scheme 9. Synthesis of UM7-inspired analogs by using Hurtley reaction 
 
Notably, the sodium borohydride-boron trifluoride combination for the reduction of the 
lactone carbonyl143 was previously investigated for the reduction of UM6 (See Scheme 
6) but it didn’t led to the desired product; on the contrary, it was successful with these 
compounds (46a, 46b, 43, Scheme 9) suggesting that the OH substitution pattern plays 
an important role for the outcome of this reaction. 
 
    Additionally, as we did for the synthesis of UM6 phenanthrene analog 35, we 
prepared the UM7 phenanthrene analog 50 (Scheme 10), starting from biphenyl-2-
carboxylate 23h, which was converted to the aldehydes 51 (69% of yield over two 
steps). Wittig reaction with (methoxymethyl)triphenylphosphonium chloride afforded 
the arylvinyl methyl ether 52 (86%), which through bismuth-catalyzed cyclization-
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aromatization was converted to the methylated phenanthrene 53 (78%) that was 
deprotected to obtain the trihydroxy- analog 50 (15%).  
 
Scheme 10. Synthesis of UM7 phenanthrene analog 50  
 
    
Finally, as last UM7-inspired analog, we planned the synthesis of urolithin E (Uro-E, 
54, Figure 14), which presents an additional hydroxyl group in the 4 position of C ring 
and, to the best of our knowledge, its preparation has not been reported. 
We reasoned that both the previously adopted strategies to obtain the dibenzopyranone 
derivatives were not suitable to prepare Uro-E. For this reason, the synthesis of Uro-E 
was performed through the approach that is reported for the high similar urolithin D 
(Figure 14).139 It started with esterification of 2-bromo-3,5-dimethoxybenzoic acid 40b 
with 2,3-dimethoxyphenol 55 to obtain 56 (75%), which through intramolecular Heck 
coupling gave the dibenzopyranone derivative 57 (10%), that was demethylated to 
obtain the desired product 54 with 68% of yield (Scheme 11). 
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Scheme 11. Synthesis of Uro-E (54) 
 
 
    In summary, we developed a synthetic strategy for UM6 and structural analogs, 
which demonstrated to be very convenient in term of high yields, short reaction times 
and versatility, as it has been confirmed by its broad application in the synthesis of 
many UM6 structural analogs (26-33, 35, 39, 50). We also explored some of the 
reported procedures for urolithins synthesis (Hurtley reaction and esterification/Heck 
reaction) for a small number of analogs (43, 46a-b, 47-49, 54), confirming the limited 
versatility and the disadvantages of these methods. 
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3. Biological evaluation and discussion of results  
All new compounds and also some intermediates were evaluated for their inhibitory 
activity on purified human LDH-A. The compounds able to cause enzyme inhibition at 
micromolar level were investigated for their activity on lactic acid production and cell 
proliferation on Raji cell line; these cells are derived from a Burkitt’s lymphoma and are 
characterized by overexpression of the MYC protein. This alteration, which drives the 
neoplastic change leading to Burkitt’s lymphoma, directly alters cell metabolism and 
causes increased LDH-A levels, rendering cells very responsive to LDH-A inhibition.112 
Most interesting results are reported in Table 2. Compounds were tested at scalar 
concentration of  25, 50, 100, 200 µM (detailed biological protocol is reported in 
Appendix A). 
 
Table 2. Activity of GF/UM6 analogs on purified human LDH-A and on lactic acid production and cell 
proliferation on Raji cells. 
Compound Structure hLDH-A IC50 (µM)a 
In cell lactate 
production 
IC50 (µM)a 
Cell growth 
IC50 (µM)a 
GF (18) 
 
70 ± 10 62 ± 5 33 ± 4 
UM6 (19) 
 
77 ± 10 36 ± 3 25 ± 2 
26 
 
83 ± 5 175 ± 30 62 ± 10 
27 
 
n.d. 
 
Inhibition at 
50µM: 73% 
 
n.d. 
 
Increase in lactate 
production 
 
n.d. 
 
Inhibition at 
50µM: 44% 
43 
 
28 
 
36 ± 3 54 ± 11 17 ± 2 
29 
HO
HO
OH
O
O
F
OH
 
28 ± 3 87 ± 10 21 ± 4 
30 
 
n.a. n.d. n.d. 
31 
 
32 ± 3 
n.d. 
 
Increase in lactate 
production  
 
<12 
32 
 
 
 
n.a. 
 
 
n.d. n.d. 
33 
 
 
n.d. 
 
Inhibition at 
200µM: 36% 
n.d. n.d. 
35 
 
 
62 ± 2 
 
 
72 ±15 
 
< 25 
 
UM7 
 (39) 
 
 
 
n.a. 
 
n.a. n.a. 
43 
 
n.a. n.d. n.d. 
46b 
 
~ 200 128 ± 4 81 ± 5 
48 
HO
OH
O
 
n.a. n.d. n.d. 
44 
 
49 
 
n.a. n.d. n.d. 
50 
 
n.d. 
Inhibition at 
100µM: 30% 
n.d. 
Inhibition at 
100µM: 50% 
n.d. 
Inhibition at 
100µM <50% 
 
Uro-E 
(54) 
 
n.a. n.d. n.d. 
aAll points were tested in triplicate with error bars indicating the standard deviations; 
n.a.= not active at 200 µM; n.d.= not determined 
 
The data obtained allowed to establish a SAR assessment for this series of derivatives. 
Compounds that showed a comparable activity to UM6 and GF, both on the purified 
enzyme and in cellular assays, present the tricyclic scaffold and the 8,9,10-
trimethoxybenzene moiety on A ring (26, 28, 29, 35). 
Compounds 28 and 29, which maintain all the four hydroxyl groups (as UM6 and GF) 
and present a small lipophilic group (chlorine and fluorine, respectively) in 2-position, 
showed the best activity on the enzyme (36µM and 28µM, respectively) retaining good 
activity in cells.  
Modification of hydroxyl in 3 position affects the activity: particularly, its removal 
preserves the activity on the enzyme but induces loss of activity in cellular assays (26). 
Compound 30, in which it is substituted with a trifluoromethyl group resulted in a 
inactive compound. Its substitution with a phenyl ring gives compound 27, for which, 
even if it showed good enzymatic inhibition (73%) and cell growth inhibition (44%) at 
50 µM, no IC50 was determined because of its not optimal solubility and precipitation at 
100 µM; however, it showed to increase lactate production suggesting different cellular 
mechanisms of action.  
Compound  31, which presents a nitrile group in 3-position and a methoxyl group in 
place of the hydroxyl group in position 10, showed good enzyme inhibition, suggesting 
that hydroxyl in position 3 could be substituted with a hydrogen bond acceptor group 
(such as a nitrile) and hydroxyl in position 10 could be not necessary for activity. 
However it  increased  lactate production and inhibited cell growth of 100% at 12 µM, 
suggesting an action based on different mechanisms. 
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Compound 32, which presents the reverse lactone function compared to UM6, did not 
show enzymatic activity, revealing the importance of lactone position in the 
tetrahydroxylated ring.  
The lactone ring-opened analog 33 showed a minimal activity on the enzyme, and has 
not been evaluated for its cellular effects. 
Importantly, UM7 (35) and Uro-E (54), with the same UM6 scaffold in which the 
8,9,10-trihydroxybenzene moiety is substituted with 8,10-dihydroxybenzene moiety, 
resulted inactive. Even if it didn’t show enzymatic activity, UM7 was also tested in cell 
assays as negative control, resulting inactive in both inhibition of lactate production and 
cell growth.  
Compound 43, UM7 analog with the reverse lacton moiety, resulting also inactive on 
the enzyme, while its analog 46b, which lacks a hydroxyl group, showed a minimal 
activity on the enzymatic assay and poor activity in cellular assays. 
The reduced analogs 48, 49 did not show any activity, suggesting the importance of the 
lacton function for this class of compounds.  
Compound  35 (phenantherene analog of UM6) showed good inhibition activity (62µM) 
on the enzyme and in lactate production (75µM), however at concentration of 25μM 
inhibited completely cell proliferation (100%), therefore suggesting an action based on 
different mechanisms involving not only LDH-A as a target. Derivative 50, 
(phenanthrene analog of UM7) was less soluble and IC50 was not determined, however 
it resulted very poorly active on the enzyme (at 100µM LDH-A inhibition was 30%) 
and also in cells, thus suggesting the relevance of the triidroxybenzene moiety 
compared to the dihydroxy one, for the LDH-A inhibition.  
    Overall, SAR suggest the following considerations for this class of inhibitors: 
-  UM6 benzopyranone scaffold has been confirmed as good structure able to mimic GF 
activity; 
- key interactions of this class of inhibitor with LDH-A probably involve 8,9,10 and 3 
hydroxyl groups, together with lactone function in 6 position;  
- substitutions in position 2 with small lipophilic groups are allowed. 
Some aspects remains to be established, particularly, if the hydroxyl group in position 
10 is necessary for the bioactivity, since it lacks in derivative 31 that is active on the 
enzyme, and if position 3 can be substituted with other hydrogen bond acceptor groups. 
    Docking studies are ongoing on the active molecules by Computational chemistry 
group to find the interactions with LDH-A and compare their putative binding mode 
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with that of GF and other reference inhibitors. These studies will allow a further 
optimization of the active compounds toward more potent inhibitors. 
    Furthermore, cell uptake studies were performed by groups of Professors Giuseppina 
Di Stefano and Laura Mercolini on the reference compounds GF and UM6, and on the 
inactive compound UM7, to evaluate the ability of this class of molecules to penetrate 
cancer cells. Intracellular concentration of GF, UM6 and UM7 were determined in Raji 
cells by treating cells (100µM) for 1h and 4h, after which cell lysates were subjected to 
LC-MS/MS analysis. 
Significant amount of each compound were detected in the intracellular fraction, 
proving they exhibit good cell penetration. (Details of this study will be published 
elsewhere.) 
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4. Conclusions  
The main project of the present thesis focused on the synthesis of a series of structural 
analogs of LDH-A inhibitor galloflavin GF, recently discovered by our group, with the 
aim to assess its SAR and gain a deeper knowledge on the key interactions involved in 
its binding to the target. Since the poor chemical manipulability of GF did not allow an 
easy access to synthesis of analogs, a structural simplification was performed which led 
to the identification of a natural dibenzopyranone, urolithin M6 (UM6). An efficient and 
versatile synthetic procedure to obtain UM6 has been developed and preliminary 
biological test showed it reproduced GF’s behaviour, making it a new hit suitable for 
our investigations.  
Initially, the synthetic route developed for UM6 has been exploited for the synthesis of 
a small library of UM6 structural analogs (26-33, 35, 39, 50) bearing the same 
dibenzopyranone scaffold or phenanthrene and biphenyl scaffolds, proving to be a 
convenient strategy in term of high yields, short reaction times and versatility. Then a 
small number of dibenzopyranone and dibenzopyrane derivatives (43, 46a-b, 47-49, 
54), were obtained through some of the previously reported procedures for urolithins 
synthesis (Hurtley reaction and esterification/Heck reaction), confirming the limited 
versatility and the disadvantages of these previously described methods. 
Biological evaluation of the new derivatives allowed us to assess SAR for this class of 
compounds. We found that compounds that showed a comparable activity to GF and 
UM6, both on the purified enzyme and in cellular assays, present the tricyclic scaffold 
and the 8,9,10-trimethoxybenzene moiety on A ring (26, 28, 29, 35). UM6 scaffold has 
been confirmed as the best structure able to mimic GF activity, since dibenzopyranone 
analogs resulted the most active compounds, while analogs carrying different scaffolds 
all showed low or no activity. Key interactions of this class of inhibitor with LDH-A 
probably involve 8,9,10 and 3 hydroxyl groups, together with lactone function in 6 
position. 
Moreover UM6 exhibited good cell penetration in preliminary cell uptake studies, as 
well as GF, predicting a desirable pharmacokinetic profile for this class of compounds. 
UM6 and the new active compounds are currently under further investigations to a 
deeper understanding of their pharmacokinetic properties and their evaluation as 
glycolytic inhibitors. 
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5. Experimental section   
General methods 
Reaction progress was monitored by TLC on pre-coated silica gel plates (Kieselgel 60 
F254, Merck) and visualized by UV254 light. Flash column chromatography was 
performed on silica gel (particle size 40-63 μM, Merck) or C18-reversed phase fully 
endcapped silica gel (particle size 40-63 μM, Sigma-Aldrich). If required, solvents were 
distilled prior to use. All reagents were obtained from commercial sources and used 
without further purification. When stated, reactions were carried out under an inert 
atmosphere. Reactions involving microwave irradiation were performed using a 
microwave synthesis system (CEM Discover® SP, 2.45 GHz, maximum power 300 W), 
equipped with infrared temperature measurement. Compounds were named relying on 
the naming algorithm developed by CambridgeSoft Corporation and used in Chem-
BioDraw Ultra 15.0. 1H-NMR and 13C-NMR spectra were recorded on Varian Gemini 
at 400 MHz and 100 MHz respectively. Chemical shifts (δH) are reported relative to 
TMS as internal standard. HPLC analysis (UM6) was performed under reversed-phase 
conditions on a Phenomenex Jupiter C18 (150x4,6 mm I.D.) column, using a binary 
mixture of 0.1% formic acid in H2O/methanol 60/40 (v/v) as mobile phase, UV 
detection at λ = 365 nm and a flow-rate of 0.8 mL/min. A loop valve of 20 µL volume 
was used. The liquid chromatograph was by Jasco Corporation (Tokyo, Japan), model 
PU-1585 UV. 
 
Experimental procedures 
Methyl 2-bromo-3,4,5-trimethoxybenzoate 21 
Commercially available methyl 3,4,5-trimethoxybenzoate 20 (10.2 g, 
45.1 mmol, 1 eq) was dissolved in CH3CN (0.1 M). The mixture was 
cooled to 0°C and N-bromosuccinimide (8.8 g, 49.6 mmol, 1.1 eq) was 
added portionwise. The reaction was let warm up to room temperature and then stirred 
at rt for 3h. After TLC showed completion, Na2S2O3 2M was added and the reaction 
mixture was stirred for 5 minutes. CH3CN was evaporated in vacuum and the mixture 
extracted 3 times with EtOAc. The combined organic phases were dried over anhydrous 
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Na2SO4, and the solvent evaporated in vacuum. The crude product was purified via 
silica gel column chromatography (Petroleum ether/EtOAc 95/5 ratio) to obtain the pure 
product 21 as a colourless viscous liquid which solidifies after standing overnight (13.1 
g, 42.8 mmol). Y= 95%. 1H NMR (400MHz, CDCl3) δ 7.13 (s, 1H), 3.90 (s, 3H), 3.89 
(s, 3H), 3.86 (s, 6H) ppm.  
 
Methyl 2-bromo-3,5-dimethoxybenzoate 21b 
Commercially available methyl 3,5-dimethoxybenzoate (5.0 g, 25.5 
mmol, 1 eq), was dissolved in CH3CN (0.1 M). The mixture was cooled 
to 0°C and N-bromosuccinimide (5.0 g, 28.1 mmol, 1.1 eq) was added 
portionwise. The reaction was let warm up to room temperature and then stirred at rt for 
3h. After TLC showed completion, Na2S2O3 2M was added and the reaction mixture 
was stirred for 5 minutes. CH3CN was evaporated in vacuum and the mixture extracted 
3 times with EtOAc. The combined organic phases were dried over anhydrous Na2SO4, 
and the solvent evaporated in vacuum. The crude product was purified via silica gel 
column chromatography (Petroleum ether/EtOAc 95/5 ratio) to obtain the pure product 
21b as a colourless viscous liquid which solidifies after standing overnight (5.6 g, 20.4 
mmol). Y= 88%. 1H NMR (400MHz, CDCl3) ) δ 6.76 (d, J = 2.7 Hz, 1H), 6.54 (d, J = 
2.4 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H) ppm. 
 
General Suzuki coupling procedure to obtain biphenyl-2-carboxylate derivatives 
(23, 23a-h) (performed in pressure tube) 
Methyl 2-bromobenzoate derivatives (21, 21a, 21b) (1.0 eq) were dissolved in 1,2-
dimethoxyethane (0.03 M), inside a pressure tube. Commercially available 
phenylboronic acid derivatives (22, 22a-g) (1.5 eq), K3PO4 (2.0 eq) and 
tetrakis(triphenylphosphine)palladium (0.1 eq) were added. The tubes were sealed, the 
reactions were heated to 120 °C and stirred for 24h. The reaction mixtures was 
transferred to round bottom flask and the solvent removed in vacuum. The crude 
products were purified via silica gel column chromatography to obtain the pure 
compounds 23, 23a-h. 
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Methyl 4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23 
The compound was obtained according to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (800 mg, 2.62 mmol, 1.0 eq) and 4-
methoxyphenylboronic acid 22 (598 mg, 3.93 mmol, 1.5 eq). The 
crude product was purified via silica gel column chromatography (Petroleum 
ether/EtOAc 90/10 ratio) to obtain the pure product as a colourless viscous liquid (714 
mg,  2.15 mmol). Y= 82%. 1H NMR (400 MHz, CDCl3) δ 7.18 (s, 1H), 7.16 (d, J= 8.7 
Hz, 2H), 6.91 (d, J= 8.7 Hz, 2H), 3.94 (s, 3H), 3.91 (s, 3H), 3.82 (s, 3H), 3.56 (s, 3H), 
3.55 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 168.42, 158.61, 152.20, 151.72, 
145.34, 130.51, 130.23, 128.84, 126.67, 116.02, 114.75, 113.19, 108.88, 61.01, 60.93, 
56.16, 55.17, 52.00 ppm. 
 
Methyl 4,5,6-trimethoxybiphenyl-2-carboxylate 23a  
The compound was obtained according  to the general Suzuki coupling 
procedure starting from methyl 2-bromo-3,4,5-trimethoxybenzoate 21 
(600 mg, 1.97 mmol, 1.0 eq) and phenylboronic acid 22a (360 mg, 
2.95 mmol, 1.5 eq). The crude product was purified via flash silica gel column 
chromatography (Petroleum ether/EtOAc 90/10 ratio) to obtain the pure product as a 
colourless viscous liquid which solidified after standing overnight (488 mg, 1.62 
mmol).Y= 82%. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.30 (m, 3H), 7.24-7.22 (m, 3H), 
3.95 (s, 3H), 3.93 (s, 3H), 3.57 (s, 3H), 3.53 (s, 3H) ppm.  
 
Methyl 4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-carboxylate 23b  
The compound was obtained according  to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (800 mg, 2.62 mmol, 1.0 eq) and 
biphenyl-4-ylboronic acid 22b (778 mg, 3.93 mmol, 1.5 eq). The 
crude product was purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 90/10 ratio) to obtain the pure product as a yellow viscous liquid (694 mg, 
1.83 mmol). Y= 70%. 1H NMR (400 MHz, CDCl3) δ 7.69-7.63 (m, 4H), 7.46 (t, J = 7.5 
Hz, 2H), 7.36 (d, J = 7.4 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 7.25 (s, 1H), 3.98 (s, 3H), 
3.95 (s, 3H), 3.62 (s, 3H), 3.57 (s, 3H) ppm. 
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Methyl 3'-chloro-4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23c 
The compound was obtained according  to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (1.0 eq) and 3-chloro-4-
methoxyphenylboronic acid 22c (733 mg, 3.93 mmol, 1.5 eq). The 
crude product was purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 95/5 ratio) to obtain the pure product as a white solid (692 mg, 1.89 
mmol). Y= 72%. 1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 7.20 (s, 1H), 7.09 (dd, J = 
8.4, 1.9 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.92 (s, 3H), 3.60 
(s, 3H), 3.58 (s, 3H) ppm. 
 
Methyl 3'-fluoro-4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23d 
The compound was obtained according  to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (800 mg, 2.62 mmol, 1.0 eq) and 3-fluoro-4-
methoxyphenylboronic acid 22d (668 mg, 3.93 mmol, 1.5 eq). The 
crude product was purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 95/5 ratio) to obtain the pure product as a yellow oil (799 mg, 2.27 mmol). 
Y= 87%. 1H NMR (400 MHz, CDCl3) δ 7.19 (s, 1H), 7.02 – 6.91 (m, 3H), 3.94 (s, 3H), 
3.92 (d, 6H), 3.60 (s, 3H), 3.58 (s, 3H) ppm.   
 
Methyl 4,5,6-trimethoxy-4'-(trifluoromethyl)biphenyl-2-carboxylate 23e 
The compound was obtained according  to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (800 mg, 2.62 mmol, 1.0 eq) and 4-
(trifluoromethyl)phenylboronic acid 22e (746 mg, 3.93 mmol, 1.5 
eq). The crude product was purified via flash silica gel column chromatography 
(Petroleum ether/EtOAc 95/5 ratio) to obtain the pure product as a white solid (922 mg, 
2.49 mmol). Y= 95%. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 2H), 7.35 (d, J 
= 8.0 Hz, 2H), 7.28 (s, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.58 (s, 3H), 3.56 (s, 3H) ppm. 
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Methyl 4'-cyano-4,5,6-trimethoxybiphenyl-2-carboxylate 23f 
The compound was obtained according to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 (800 mg, 2.62 mmol, 1.0 eq) and 4-
cyanophenylboronic acid 22f (578 mg, 3.93 mmol, 1.5 eq). The 
crude product was purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 95/5 ratio) to obtain the pure product as a white solid (849 mg, 2.59 
mmol). Y= 99%. 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 
8.4 Hz, 2H), 7.30 (s, 1H), 3.96 (s, 3H), 3.95 (s, 3H) 3.58 (s, 3H), 3.57 (s, 3H) ppm. 
 
Methyl 2',3',4,4'-tetramethoxy-[1,1'-biphenyl]-2-carboxylate 23g 
The compound was obtained according  to the general Suzuki 
coupling procedure starting from commercially available methyl 
2-bromo-3,4,5-trimethoxybenzoate 21a (250 mg, 1.02 mmol, 1.0 
eq) and 2,3,4-trimethoxyphenylboronic acid 22g (320 mg, 1.53 
mmol, 1.5 eq). The crude product was purified via flash silica gel column 
chromatography (Petroleum ether/EtOAc 95/5 ratio) to obtain the pure product as a 
white solid (340 mg, 1.02 mmol). Y= 100%. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 
2.8 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.06 (dd, J = 8.5, 2.8 Hz, 1H), 6.91 (d, J = 8.5 Hz, 
1H), 6.70 (d, J = 8.5 Hz, 1H), 3.89 (d, J = 2.0 Hz, 6H), 3.87 (s, 3H), 3.67 (s, 3H), 3.53 
(s, 3H) ppm. 
 
Methyl 4,4',6-trimethoxybiphenyl-2-carboxylate 23h 
The compound was obtained according to the general Suzuki 
coupling procedure starting from methyl 2-bromo-3,5-
dimethoxybenzoate 21b (800 mg, 2.91 mmol, 1.0 eq) and 4-
methoxyphenylboronic acid 22 (663 mg, 4.36 mmol, 1.5 eq). The 
crude product was purified via silica gel column chromatography (Petroleum 
ether/EtOAc 95/5 ratio) to obtain the pure product as a colourless viscous liquid (748 
mg, 2.47 mmol). Y= 85%. 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.6 Hz, 2H), 6.91 
(d, J = 8.6 Hz, 2H), 6.86 (d, J = 2.3 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.87 (s, 3H), 3.83 
(s, 3H), 3.73 (s, 3H), 3.56 (s, 3H) ppm. 
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General procedure for ester hydrolysis: biphenyl-2-carboxylate derivatives (23, 
23a-h) to free biphenyl-2-carboxylic acid derivatives (24, 24a-h) and methyl-2-
bromobenzoates 21, 21b to free acids 40, 40b. 
Esters 23, 23a-h, 21, 21b were treated with a 1/1 mixture of 4M NaOH (10 eq) and 
EtOH at 60 °C for 1-2h. After TLC showed absence of starting material the reaction 
mixtures were treated with 37% HCl until acidic pH, brine was added and the mixtures 
were extracted 3 times with EtOAc. The combined organic phases were dried over 
anhydrous Na2SO4, and the solvent evaporated in vacuum to obtain free carboxylic 
acids which were used in the next step without further purification. 
 
4,4',5,6-tetramethoxybiphenyl-2-carboxylic acid 24 
Methyl 4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23 (1590 mg, 
4.78 mmol) was treated following the general procedure for ester 
hydrolysis and gave free acid 24 as a white solid (1445 mg, 4.54 
mmol). Y= 95% (crude). 1H NMR (400 MHz, DMSO-d6) δ 12.48 (s, 
1H), 7.12 (s, 1H), 7.10 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 3.85 (s, 3H), 3.82 
(s, 3H), 3.78 (s, 3H), 3.46 (s, 3H) ppm. 
 
4,5,6-trimethoxybiphenyl-2-carboxylic acid 24a 
Methyl 4,5,6-trimethoxybiphenyl-2-carboxylate 23a (340 mg, 1.12 
mmol) was treated following the general procedure for ester hydrolysis 
and gave 24a as a white solid (320 mg, 1.11 mmol). Y= 99% (crude). 
1H NMR (400 MHz, DMSO-d6) δ 12.53 (br, OH), 7.36-7.29 (m, 3H), 7.19-7.17 (m, 
3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.47 (s, 3H) ppm. 
 
4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-carboxylic acid 24b 
Methyl 4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-carboxylate 
23b (610 mg, 1.61 mmol) was treated following the general 
procedure for ester hydrolysis and gave 24b as a light yellow 
solid (590 mg, 1.59 mmol). Y= 99% (crude). 1H NMR(400 
MHz, DMSO-d6) δ 12.59 (br, OH), 7.73 – 7.71 (m, 2H), 7.66 (d, J = 8.4 Hz, 2H), 7.48 
(t, J = 7.6 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.19 (s, 1H), 3.88 
(s, 3H), 3.84 (s, 3H), 3.52 (s, 3H) ppm. 
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3'-chloro-4,4',5,6-tetramethoxybiphenyl-2-carboxylic acid 24c 
Methyl 3'-chloro-4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23c 
(870 mg, 2.37 mmol) was treated following the general procedure for 
ester hydrolysis and gave 24c as a white solid (830mg, 2.35 mmol). 
Y= 99% (crude). 1H NMR (400 MHz, DMSO-d6) δ 12.64 (br, OH), 
7.20 (d, J = 1.7 Hz, 1H), 7.18 (s, 1H), 7.12 – 7.11 (m, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 
3.83 (s, 3H), 3.50 (s, 3H) ppm. 
 
3'-fluoro-4,4',5,6-tetramethoxybiphenyl-2-carboxylic acid 24d 
Methyl 3'-fluoro-4,4',5,6-tetramethoxybiphenyl-2-carboxylate 23d 
(800 mg, 2.28 mmol) was treated following the general procedure for 
ester hydrolysis and gave 24d as a white solid (720 mg, 2.14 mmol). 
Y= 93% (crude). 1H NMR (400 MHz, DMSO-d6) δ 12.61 (br, OH), 
7.17 (s, 1H), 7.13 (t, J = 8.8 Hz, 1H), 7.02 (dd, J = 12.4, 2.0 Hz, 1H), 6.93-6.91 (m, 1H), 
3.86 (s, 6H), 3.82 (s, 3H), 3.50 (s, 3H) ppm. 
 
4,5,6-trimethoxy-4'-(trifluoromethyl)biphenyl-2-carboxylic acid 24e 
Methyl 4,5,6-trimethoxy-4'-(trifluoromethyl)biphenyl-2-
carboxylate 23e (1.15 g, 3.11 mmol) was treated following the 
general procedure for ester hydrolysis and gave 24e as a white solid 
(1.11 g, 3.11 mmol). Y= 100% (crude). 1H NMR (400 MHz, 
DMSO-d6) δ 12.68 (br, OH), 7.71 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 7.27 (s, 
1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.51 (s, 3H) ppm. 
 
4'-cyano-4,5,6-trimethoxybiphenyl-2-carboxylic acid 24f 
Methyl 4'-cyano-4,5,6-trimethoxybiphenyl-2-carboxylate 23f (940 
mg, 2.87 mmol) was treated following the general procedure for 
ester hydrolysis and gave 24f as a white solid (910 mg, 2.90 
mmol). Y= 101% (crude). 1H NMR (400 MHz, DMSO-d6) δ 12.62 
(br, OH), 7.97 (s, 1H), 7.85-7.80 (m, 2H), 7.25 – 7.22 (m, 2H), 3.88 (s, 3H), 3.84 (s, 
3H), 3.50 (s, 3H) ppm. 
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2',3',4,4'-tetramethoxy-[1,1'-biphenyl]-2-carboxylic acid 24g 
Methyl 2',3',4,4'-tetramethoxy-[1,1'-biphenyl]-2-carboxylate 23g 
(350 mg, 1.05 mmol) was treated following the general procedure 
for ester hydrolysis o and gave 24g as a white solid (300 mg, 0.94 
mmol). Y= 90% (crude). 1H NMR (401 MHz, Methanol-d4) δ 7.39 
(d, J = 2.7 Hz, 1H), 7.23 (d, J = 8.5, 1H), 7.11 (dd, J = 8.5, 2.8 Hz, 1H), 6.90 (d, J = 8.5 
Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 3.87 (s, 6H), 3.83 (s, 3H), 3.52 (s, 3H) ppm. 
 
4,4',6-trimethoxybiphenyl-2-carboxylic acid 24h 
Methyl 4,4',6-trimethoxybiphenyl-2-carboxylate 23h (600 mg, 1.81 
mmol) was treated following the general procedure for ester 
hydrolysis and gave 24h as a white solid (548 mg, 1.72 mmol). Y= 
95% (crude). 1H NMR (400 MHz, DMSO-d6) δ 12.54 (br, OH), 7.06 
(d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.74-6.73 (m, 2H), 3.81 (s, 3H), 3.76 (s, 
3H), 3.67 (s, 3H) ppm. 
 
2-bromo-3,4,5-trimethoxybenzoic acid 40 
The compound was obtained starting from methyl 2-bromo-3,4,5-
trimethoxybenzoate 21 following the general procedure for ester 
hydrolysis as a white solid. Y= 95%. 1H NMR (400 MHz, DMSO-d6) 
δ 13.39 (s, OH), 7.17 (s, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H) 
ppm. 
 
2-bromo-3,5-dimethoxybenzoic acid 40b  
The compound was obtained starting from methyl 2-bromo-3,5-
dimethoxybenzoate 21b following the general procedure for ester 
hydrolysis as a white solid. Y= 97 %. 1H NMR (400 MHz, DMSO-d6) 
δ 13.37 (s, OH), 6.77 (d, J = 2.5 Hz, 2H), 3.87 (s, 3H), 3.81 (s, 3H) 
ppm. 
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3,8,9,10-tetramethoxy-6H-benzo[c]chromen-6-one  25 
Route A. 4,4',5,6-tetramethoxybiphenyl-2-carboxylic acid 24 was 
added 50 mL of a 1/1 H2O/CH3CN mixture. K2S2O8 (3880 mg, 
14.353 mmol, 3.0 equiv) and AgNO3 (81 mg, 0.478 mmol, 0.1 
equiv) were added and the reaction was stirred at 60°C for 48h. 
CH3CN was evaporated in vacuum and the mixture extracted 3 times with EtOAc. The 
combined organic phases were dried over anhydrous Na2SO4, and the solvent 
evaporated in vacuum. The crude product was purified via silica gel column 
chromatography (Petroleum ether/EtOAc 85/15 ratio) to obtain the pure product as an 
off white solid (yield 30%). 
Route B. To a solution of 4,4',5,6-tetramethoxybiphenyl-2-carboxylic acid 24 (540 mg, 
1.70 mmol) in ClCH2CH2Cl (18 mL) was added N-iodosuccinimide (950 mg, 4.24 
mmol, 2.5 eq) in one portion and the mixture was heated to 75 °C for 3 h. After 
completion of the reaction, EtOAc (35 mL) was added and the mixture was washed with 
sat. Na2S2O3 (20 mL), then with H2O (2 × 20 mL). The organic layer was dried  over 
anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified via  silica 
gel column chromatography (Petroleum ether/EtOAc, 92:8) to obtain the pure product 
as an off white solid (yield 69%). 
1H NMR: (400MHz, CDCl3) δ 8.74 (d, J = 8.0, 1H), 7.72 (s, 1H), 6.91-6.86 (m, 2H), 
4.04 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 3.88 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 161.50, 160.44, 153.10, 151.96, 150.62, 127.77, 123.49, 116.26, 112.26, 110.81, 
110.18, 108.29, 101.67, 61.33, 60.61, 56.41, 55.72 ppm. 
 
General procedure (Route B) to obtain 6H-benzo[c]chromen-6-one derivatives 
(25a-h)  
To a solution of biphenyl-2-carboxylic acid (24a-h) in ClCH2CH2Cl (0.1 M) was added 
N-iodosuccinimide (2.5 eq) in one portion and the mixture was heated to 75 °C for 3 h. 
After completion of the reaction, EtOAc was added and the mixture was washed with 
sat. Na2S2O3 then with H2O. The organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude products was purified via silica gel column 
chromatography to obtain pure 6H-benzo[c]chromen-6-ones (25a-h). 
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8,9,10-trimethoxy-6H-benzo[c]chromen-6-one 25a 
The compound was obtained according to the general procedure 
(Route B) starting from 4,5,6 trimethoxybiphenyl-2-carboxylic acid 
24a (240 mg, 0.83  mmol, 1 eq). The crude product was purified via 
flash silica gel column chromatography (Petroleum ether/EtOAc 90/10 ratio) to obtain 
the pure product as a white solid (190 mg, 0.66 mmol). Y= 80% 1H NMR (400 MHz, 
CDCl3) δ 8.85 (d, J = 8.2 Hz, 1H), 7.77 (s, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.39 – 7.28 (m, 
2H), 4.04 (s, 3H), 4.00 (s, 3H), 3.99 (s, 3H) ppm. 
 
8,9,10-trimethoxy-3-phenyl-6H-benzo[c]chromen-6-one 25b 
The compound was obtained according to the general procedure 
(Route B) starting from 4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-
carboxylic acid 24b (560mg, 1.48 mmol, 1 eq). The crude product 
was purified via flash silica gel column chromatography 
(Petroleum ether/EtOAc 90/10 ratio) to obtain the pure product as a light yellow solid 
(510 mg, 1.41 mmol). Y= 95%. 1H NMR (400 MHz, CDCl3) δ 8.89 (d, J = 8.7 Hz, 1H), 
7.78 (s, 1H), 7.70 – 7.64 (m, 2H), 7.62 – 7.55 (m, 2H), 7.49 (t, J = 7.5 Hz, 2H), 7.41 (t, J 
= 7.5 Hz, 1H), 4.06 (s, 3H), 4.02 (s, 6H) ppm. 
 
2-chloro-3,8,9,10-tetramethoxy-6H-benzo[c]chromen-6-one 25c 
The compound was obtained according to the general procedure 
(Route B) starting from 3'-chloro-4,4',5,6-tetramethoxybiphenyl-2-
carboxylic acid 24c (830 mg, 2.35 mmol, 1 eq). The crude product 
was purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 90/10 ratio) to obtain the pure product as an off white solid (520 mg, 1.48 
mmol). Y= 63%. 1H NMR (400 MHz, CDCl3) δ  8.85 (s, 1H), 7.71 (s, 1H), 6.90 (s, 1H), 
4.04 (s, 3H), 3.99 (s, 6H), 3.96 (s, 3H) ppm. 
 
2-fluoro-3,8,9,10-tetramethoxy-6H-benzo[c]chromen-6-one 25d 
The compound was obtained according to the general procedure 
(Route B) starting from 3'-fluoro-4,4',5,6-tetramethoxybiphenyl-2-
carboxylic acid 24d (705 mg, 2.10 mmol, 1 eq). The crude product 
O
O
O
O
O
F
O
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was purified via flash silica gel column chromatography (Petroleum ether/EtOAc 90/10 
ratio) to obtain the pure product as an off white solid (351 mg, 1.05 mmol). Y= 50%. 1H 
NMR (400 MHz, CDCl3) δ 8.56 (d, J = 13.8 Hz, 1H), 7.72 (s, 1H), 6.93 (d, J = 7.7 Hz, 
1H), 4.03 (s, 3H), 3.99 (s, 6H), 3.96 (s, 3H) ppm.   
 
8,9,10-trimethoxy-3-(trifluoromethyl)-6H-benzo[c]chromen-6-one 25e 
The compound was obtained according to the general procedure 
(Route B) starting from 4,5,6-trimethoxy-4'-
(trifluoromethyl)biphenyl-2-carboxylic acid 24e (670 mg, 1.88 
mmol, 1 eq). The crude product was purified via flash silica gel 
column chromatography (Petroleum ether/EtOAc 90/10 ratio) to obtain the pure product 
as a light yellow solid (460 mg, 1.30 mmol). Y= 69%. 1H NMR (400 MHz, CDCl3) δ 
8.99 (d, J = 8.6 Hz, 1H), 7.78 (s, 1H), 7.60 (s, 1H), 7.56 (d, J = 8.6 Hz, 1H), 4.05 (s, 
3H), 4.02 (s, 3H), 4.01 (s, 3H) ppm. 
 
8,9,10-trimethoxy-6-oxo-6H-benzo[c]chromene-3-carbonitrile 25f 
The compound was obtained according to the general procedure 
(Route B) starting from 4'-cyano-4,5,6-trimethoxybiphenyl-2-
carboxylic acid 24f (300 mg, 0.96 mmol, 1 eq). The crude 
product was purified via flash silica gel column chromatography 
(Petroleum ether/EtOAc 85/15 ratio) to obtain the pure product as a white solid (100 
mg, 0.32 mmol). Y= 33%. 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 8.5 Hz, 1H), 7.77 
(s, 1H), 7.61 (s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 4.05 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H) 
ppm. 
 
1,2,3,8-tetramethoxy-6H-benzo[c]chromen-6-one 25g 
The compound was obtained according to the general procedure 
(Route B) starting from 2',3',4,4'-tetramethoxy-[1,1'-biphenyl]-2-
carboxylic acid 24g (290 mg, 0.91 mmol, 1 eq). The crude 
product was purified via flash silica gel column chromatography 
(Petroleum ether/EtOAc 90/10 ratio) to obtain the pure product 
as a white solid (70 mg, 0.22 mmol). Y= 24%. (impurities detected) 1H NMR (401 
MHz, Chloroform-d) δ 8.78 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 2.9 Hz, 1H), 7.34 (dd, J = 
9.1, 3.0 Hz, 1H), 6.70 (s, 1H), 3.90 (m, 9H), 3.88 (s, 3H) ppm. 
O
O
O
CN
O
O
59 
 
 
3,8,10-trimethoxy-6H-benzo[c]chromen-6-one 25h  
The compound was obtained according to the general procedure 
(Route B) starting from 4,4',6-trimethoxybiphenyl-2-carboxylic acid 
24h (300 mg, 1.04 mmol, 1 eq). The crude product was purified via 
flash silica gel column chromatography (Petroleum ether/EtOAc 95/5 
ratio) to obtain the pure product as a white solid (106 mg, 0.37 mmol). Y= 36 %.  1H 
NMR (400 MHz, CDCl3) δ 8.75 (d, J = 9.9 Hz, 1H), 7.47 (d, J = 2.4 Hz, 1H), 6.89 – 
6.79 (m, 3H), 4.01 (s, 3H), 3.92 (s, 3H), 3.87 (s, 3H) ppm. 
 
 
General procedure to obtain biphenyl-2-carbaldehyde derivatives 36, 51 
Step 1) Biphenyl-2-carboxylate derivatives (23, 23h) were dissolved in dry DCM (0.2 
M) and the mixtures were cooled to 0 °C. Diisobutylaluminum hydride (DIBAL) 1.0 M 
in hexane (4.2 eq) was added dropwise. The reaction mixtures were then stirred for 3h 
at rt. H2O and DCM were added and the mixtures were filtered to remove the 
precipitate. The phases were separated and the aqueous phase was extracted with DCM. 
The combined organic phase was dried over anhydrous Na2SO4 and the solvent 
evaporated in vacuum. The crude products were purified as indicated to obtain the pure 
biphenyl alcohol intermediate (23’, 23h’).  
Step 2) Alcohol intermediate 23’, 23h’ were dissolved in CH2Cl2 (0.1 M). PCC (1.5 eq) 
was added and the reactions were stirred at room temperature for 4 hours. The reaction 
mixtures were filtered on celite and the solvent evaporated to yield the crude products 
36, 51, which were purified as indicated. 
 
(4,4',5,6-tetramethoxybiphenyl-2-yl)methanol 23’ 
The compound was obtained according  to the general procedure 
(step 1) starting from methyl 4,4',5,6-tetramethoxybiphenyl-2-
carboxylate 23 (650 mg, 1.96 mmol, 1 eq). The crude product was 
purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 80/20 ratio) to obtain the pure product as a light brown viscous liquid (435 
mg, 1.43 mmol, 1 eq). Y= 73%. 1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 8.3 Hz, 2H), 
6.96 (d, J = 8.4 Hz, 2H), 6.89 (s, 1H), 4.41 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.85 (s, 
3H), 3.60 (s, 3H) ppm. 
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4,4',5,6-tetramethoxybiphenyl-2-carbaldehyde 36 
The compound was obtained according to the general procedure 
(step 2) starting from (4,4',5,6-tetramethoxybiphenyl-2-
yl)methanol 23’ (359 mg, 1.18 mmol, 1 eq). The crude product 
was used in the next step without further purification (207 mg, 
0.68 mmol). Y= 58%. 1H NMR (400 MHz, CDCl3) δ 9.66 (s, 1H), 7.33 (s, 1H), 7.23 (d, 
J = 8.5 Hz, 2H), 6.99-6.93 (m, 2H), 3.98 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H), 3.57 (s, 3H) 
ppm.  
 
(4,4',6-trimethoxybiphenyl-2-yl)methanol 23h’  
The compound was obtained according to the general procedure 
(step 1) starting from methyl 4,4',6-trimethoxybiphenyl-2-
carboxylate 23h (520 mg, 1.71 mmol, 1 eq). The crude product was 
purified via flash silica gel column chromatography (Petroleum 
ether/EtOAc 80/20 ratio) to obtain the pure product as a white solid (352 mg, 1.28 
mmol). Y= 75%. 1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 
8.5 Hz, 2H), 6.72 (d, J = 2.3 Hz, 1H), 6.49 (d, J = 2.3 Hz, 1H), 4.42 (d, J = 5.3 Hz, 2H), 
3.87 (s, 3H), 3.84 (s, 3H), 3.71 (s, 3H) ppm. 
 
4,4',6-trimethoxybiphenyl-2-carbaldehyde 51          
The compound was obtained according to the general procedure 
(step 2) starting from (4,4',6-trimethoxybiphenyl-2-yl)methanol 
23h’ (350 mg, 1.28 mmol, 1 eq). The crude product was purified 
via flash silica gel column chromatography (Petroleum 
ether/EtOAc 90/10 ratio) to obtain the pure 51 as a white solid (320 mg, 1.17 mmol). 
Y= 92%. 1H NMR (400 MHz, CDCl3) δ  9.73 (s, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.09 (d, 
J = 2.5 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.75 (d, J = 2.5 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 
3H), 3.77 (s, 3H) ppm. 
 
 
General Wittig procedure to obtain (2-methoxyvinyl)biphenyl derivatives (37, 52) 
(Methoxymethyl)triphenylphosphonium chloride (1.5 eq) was dissolved in dry THF (0.3 
M) and the mixture was cooled to 0°C under inert atmosphere. LiHMDS 1.0 M in THF 
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(2 eq) was slowly added and the reaction was stirred for 10 minutes. Biphenyl-2-
carbaldehyde derivative (36, 51) (1.0 eq) was dissolved in dry THF (0.2 M) in a 
separate flask and the solution was added slowly to the reaction mixture. The reaction 
was warmed to room temperature and stirred for 1 hour. H2O was added and the 
mixture was extracted 3 times with EtOAc. The combined organic phases were dried 
over anhydrous Na2SO4, and the solvent evaporated in vacuum. The crude product was 
purified via silica gel column chromatography to obtain the pure product (37, 52) as a 
mixture of E/Z isomers. 
 
2,3,4,4'-tetramethoxy-6-(2-methoxyvinyl)biphenyl 37 
The compound was obtained according  to the general Wittig 
procedure starting from 4,4',5,6-tetramethoxybiphenyl-2-
carbaldehyde 36 (207 mg, 0.69 mmol, 1 eq).The crude product 
was purified via silica gel column chromatography (Petroleum ether/EtOAc 90/10 ratio) 
to obtain the pure product as a colourless viscous liquid (128 mg, 0.39 mmol). Y= 56% 
(60/40 mixture of E/Z isomers). 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.18-7.15 
(m, 2H), 6.94 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 12.9 Hz, 1H, trans), 6.70 (s, 1H), 5.97 (d, 
J = 7.2 Hz, 1H, cis), 5.52 (d, J = 12.9 Hz, 1H, trans), 4.92 (d, J = 7.2 Hz, 1H, cis), 3.91 
(s, 3H), 3.89 (s, 3H), 3.85 (s, 3H), 3.74 (s, 0.40x3H), 3.57 (s, 0.60x3H), 3.56 (s, 
0.40x3H), 3.48 (s, 0.60x3H) ppm. 
 
2,4,4'-trimethoxy-6-(2-methoxyvinyl)biphenyl 52 
The compound was obtained according  to the general Wittig 
procedure starting from 4,4',6-trimethoxybiphenyl-2-carbaldehyde 
51 (210 mg, 0.77 mmol, 1 eq). The crude product was purified via 
silica gel column chromatography (Petroleum ether/EtOAc 90/10 ratio) to obtain the 
pure product as a colourless viscous liquid  (200 mg, 0.66 mmol). Y= 86% (50 /50 
mixture of E/Z isomers). 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.3 Hz, 1H), 7.21-
7.17 (m, 4H), 6.99-6.91 (m, 4H), 6.93 (d, J = 12.9 Hz, 1H, trans), 6.60 (d, J = 2.2 Hz, 
1H), 6.45-6.43 (m, 2H), 6.02 (d, J = 7.3 Hz, 1H, cis), 5.58 (d, J = 12.9 Hz, 1H, trans), 
4.99 (d, J = 7.3 Hz, 1H, cis), 3.88 (s, 3H), 3.87 (s, 3H), 3.86 (d, 6H), 3.75 (s, 3H), 3.72 
(s, 3H), 3.71 (s, 3H), 3.50 (s, 3H) ppm. 
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General Bismuth-cyclisation procedure to obtain methoxy-protected phenantrene 
derivatives (38, 53) 
(2-methoxyvinyl)biphenyl derivatives (37, 52) (1 eq) was dissolved in 1,2-
dichloroethane (0.1-0.2 M) under nitrogen atmosphere. Bismuth(III) 
trifluoromethanesulfonate (0.05 eq) was added and the reaction was stirred at room 
temperature for 30 minutes. After TLC showed full conversion, the solvent was 
evaporated. The crude product was purified via silica gel column chromatography to 
obtain the pure products. 
 
2,3,4,7-tetramethoxyphenanthrene 38 
The compound was obtained according to the general Bismuth-
cyclization procedure starting from 2,3,4,4'-tetramethoxy-6-(2-
methoxyvinyl)-1,1'-biphenyl 37 (127 mg, 0.38 mmol, 1 eq). The 
crude product was purified via silica gel column chromatography (Petroleum 
ether/EtOAc 95/5 ratio) to obtain the pure product as a white solid (74 mg, 0.25 mmol). 
Y= 65%. 1H NMR (400 MHz, CDCl3) δ 9.40 (d, J = 9.2 Hz, 1H), 7.57 (s, 2H), 7.27 – 
7.19 (m, 2H), 7.06 (s, 1H), 4.02 (s, 3H), 4.00 (s, 1H), 3.99 (s, 3H), 3.94 (s, 3H) ppm. 
 
2,4,7-trimethoxyphenanthrene 53 
The compound was obtained according to the general Bismuth-
cyclization procedure starting from 2,4,4'-trimethoxy-6-(2-
methoxyvinyl)biphenyl 52 (200 mg, 0.66 mmol, 1 eq). The crude 
product was purified via silica gel column chromatography (Petroleum ether/EtOAc 
95/5 ratio) to obtain the pure product as a white solid (140 mg, 0.52 mmol). Y= 78%. 1H 
NMR (400 MHz, CDCl3) δ 9.54 – 9.44 (m, 1H), 7.68-7.61 (m, 2H), 7.29-7.26 (m, 2H), 
6.90 (d, J = 2.5 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 4.10 (s, 3H), 3.97 (s, 3H), 3.96 (s, 3H) 
ppm. 
 
 
General procedure of Hurtley condensation for the synthesis of benzocoumarins 
42, 42b, 46a, 46b. 
Commercially available phenol derivatives (resorcinol 41 or phloroglucinol 45) (2 eq) 
and 2-bromobenzoic acid derivatives 40, 40b (synthesized by us), or commercially 
available 2-bromo-5-methoxybenzoic acid 44a and 2-bromobenzoic acid 44b  (1 eq) 
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were added to a 4 M NaOH solution (2 eq) and heated at 60 °C for 30 min under N2 
atmosphere. Aq. CuSO4 10% (0.1 eq) was added dropwise to the hot reaction and 
heating was continued at 95 °C for 3 h. The reaction mixture was cooled to room 
temperature. The precipitate was filtered off, washed with water and dried under 
vacuum.  
 
3-hydroxy-8,9,10-trimethoxy-6H-benzo[c]chromen-6-one 42 
According to the general procedure of Hurtley condensation, 2-
bromo-3,4,5-trimethoxybenzoic acid  40 (1 g, 3.44 mmol, 1 eq) 
and resorcinol 41 (758 mg, 6.88 mmol, 2 eq) afforded 42 (140 mg, 
0.47 mmol) as an off-white solid. Y= 14%. 1H NMR (401 MHz, 
DMSO-d6) δ 10.28 (s, 1H), 8.58 (d, J = 9.0 Hz, 1H), 7.58 (s, 1H), 6.83 (dd, J = 9.0, 2.6 
Hz, 1H), 6.73 (d, J = 2.5 Hz, 1H), 3.93 (s, 5H), 3.89 (s, 3H)ppm. 
 
3-hydroxy-8,10-dimethoxy-6H-benzo[c]chromen-6-one 42b  
According to the general procedure of Hurtley condensation, 2-
bromo-3,5-dimethoxybenzoic acid 40b (960 mg, 3.52 mmol,1 eq) 
and resorcinol 41 (776 mg, 7.05 mmol, 2 eq) afforded 42b as a 
yellow-green powder (30 mg, 0.11 mmol). (Y= 3%) 1H NMR (401 
MHz, DMSO-d6) δ 8.66 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 2.5 Hz, 1H), 7.12 (d, J = 2.5 
Hz, 1H), 6.74-6.69 (m, 2H), 4.03 (s, 3H), 3.90 (s, 3H) ppm. 
 
1,3-dihydroxy-8-methoxy-6H-benzo[c]chromen-6-one 46a144  
According  to the general procedure of Hurtley condensation, 2-
bromo-5-methoxybenzoic acid  44a (1.0 g, 4 mmol, 1 eq) and 
phloroglucinol 45 (1.09 g, 8.66 mmol, 2 eq) afforded product 46a 
as an off-white solid (700mg, mmol).Y= 68%. 1H NMR (400 
MHz, DMSO-d6) δ 10.81 (br, OH), 10.03 (br, OH), 8.90 (d, J = 9.2 Hz, 1H), 7.62 (d, J = 
2.7 Hz, 1H), 7.44 (dd, J = 9.2, 2.9 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 6.26 (d, J = 2.1 Hz, 
1H), 3.87 (s, 3H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 160.6, 158.3, 157.3, 156.8, 
152.4, 128.8, 127.7, 123.2, 119.7, 110.9, 99.8, 98.7, 94.9, 55.40 ppm. 
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1,3-dihydroxy-6H-benzo[c]chromen-6-one 46b142 
According to the general procedure of Hurtley condensation, 2-
bromobenzoic acid  44b (2.01 g, 10 mmol, 1 eq) and phloroglucinol 
45 (2.52 g, 20 mmol, 2 eq) product 46b as an off-white solid (1.89 g, 
8.3 mmol). Y= 83 %. 1H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 
OH), 10.14 (s, OH), 8.96 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.83 (t, J = 7.8 
Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 6.43 – 6.37 (m, 1H), 6.28 – 6.23 (m, 1H) ppm; 13C 
NMR (100 MHz, DMSO-d6) δ 160.7, 159.2, 157.6, 153.3, 135.4, 134.9, 129.3, 126.3, 
125.8, 118.4, 99.8, 98.6, 95.1 ppm.   
 
2, 3 dimethoxyphenol 55146 
To a mixture of 30% H2O2 (2.02 mL, 19.8 mmol, 2.2 eq) of and boric 
acid (2.78 g, 45.0 mmol, 5 eq) in 30mL THF was added 0.9 mL of 
sulfuric acid. The mixture was stirred a t rt for 30 min and a solution of 
2,3-dimethoxybenzaldehyde (1.5 g, 9.0 mmol, 1 eq) in 10mL THF was added. The 
mixture was heated to 50 °C for 24h, quenched with satured NaHCO3 and filtered. The 
filtrate was extracted with Et2O and the combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. Purification by column flash chromatography (EtPet 
85/EtOAc 15) afforded  1.2g (7.65 mmol) of product, white powder (Y= 85%). 1H 
NMR (401 MHz, Chloroform-d) δ 6.93 (t, J = 8.3 Hz, 1H), 6.60 (dd, J = 8.2, 1.4 Hz, 
1H), 6.48 (dd, J = 8.3, 1.4 Hz, 1H), 5.79 (s, 1H), 3.90 (s, 3H), 3.86 (s, 3H) ppm. 
 
2,3-dimethoxyphenyl 2-bromo-3,5-dimethoxybenzoate 56 
Oxalyl chloride (0.13mL, 1.49mmol, 1.1 eq) and DMF (1 drop, 
cat) were added to a 0 °C suspension of 2-bromo-3,5-
dimethoxybenzoic acid 40b (355mg, 1.36mmol, 1 eq) in CH2Cl2 
(2.5mL). The reaction mixture was stirred for 5min at 0 °C and 
then for 16h at rt. The reaction mixture was concentrated under reduced pression. The 
resulting oil was solubilized in CH2Cl2 (1.20mL) and cooled to 0 °C. 2,3 
dimethoxyphenol 55 (230mg, 1.49 mmol, 1.1 eq) and trimethylamine (0.3mL, 2.03 
mmol, 1.5 eq) were added and the mixture was stirred for 5min. Acetonitrile (1.20 mL) 
was finally added and the resulting mixture was stirred at rt for 16h. The reaction was 
quenched with a satured solution of ammonium chloride and the layers were separated. 
The aqueous phase was extracted with CH2Cl2 and the combined organic layers were 
O
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dried over Na2SO4 and concentrated in vacuo. Purification by column flash 
chromatography (EtPet 92/EtOAc 8) afforded 400mg (1.01 mmol) of product as white 
powder (Y= 75%). 1H NMR (401 MHz, Chloroform-d) δ 7.12 – 7.04 (m, 2H), 6.87 (d, J 
= 1.2 Hz, 1H), 6.85 (d, J = 1.2 Hz, 1H), 6.66 (dd, J = 2.8, 1.2 Hz, 1H), 3.92 (s, 3H), 
3.90 (s 3H), 3.88 (s, 3H), 3.87 (s, 3H) ppm. 
 
3,4,8,10-tetramethoxy-6H-benzo[c]chromen-6-one 57 
Sodium acetate (180mg, 2.22mmol, 2eq), S-Phos (45mg, 
0.11mmol, 0.1 eq) and Pd(OAc)2 (24mg, 0.11mmol, 0.1 eq) were 
added to a solution of  2,3-dimethoxyphenyl 2-bromo-3,5-
dimethoxybenzoate 56 (440 mg, 1.11mmol, 1eq) in dry 
dimethylacetamide (DMA) (20mL) under inert atmosphere. The reaction mixture was 
stirred at 130 °C for 3 days. The reaction was quenched by addition of water and the 
mixture extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure. The remaining DMA was eliminated  by 
distillation under reduced pressure. The crude oil was purified by column flash 
chromatography (DCM 99.5/MeOH 0.5) afforded 50mg (0.16 mmol) of product as 
yellow powder (Y= 14%) (Starting material recovered 170 mg). 1H NMR (401 MHz, 
Chloroform-d) δ 8.55 (d, J = 9.3 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 6.88 – 6.86 (m, 1H), 
6.85 (s, 1H), 4.00 (s, 3H), 4.00 (s, 3H), 3.95 (s, 3H), 3.92 (s, 3H) ppm. 
 
 
General demethylation procedure to obtain the final deprotected UM6 (19), 26-33, 
35, 39, 43, 50, 54 
O-Methoxy protected compound was dissolved in dry DCM (0.03-0.09 M) in a flame 
dried flask and the mixture was cooled to -78°C. BBr3 1.0M in DCM (2 eq per methoxy 
group) was slowly added dropwise. The reaction was let warm up to room temperature 
and stirred for 24-48h. MeOH was added and the solvent was removed in vacuum. The 
crude products were purified as specified. 
 
3,8,9,10-tetrahydroxy-6H-benzo[c]chromen-6-one 19 (UM6) 
The compound was obtained starting from 3,8,9,10-tetramethoxy-
6H-benzo[c]chromen-6-one 25 (105 mg, 0.332 mmol, 1.0 equiv), 
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following the general demethylation procedure. The crude product was purified via C18 
silica gel reverse phase column chromatography (H2O/MeOH/HCOOH elution gradient 
from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to obtain the product in a mixture with a 
minor dark impurity not detectable using NMR, which was removed washing the 
product with small amounts of MeOH, yielding the pure compound as a grey solid 
(yield 58%).  
The product was also obtained starting from 3-hydroxy-8,9,10-trimethoxy-6H-
benzo[c]chromen-6-one 42 (130 mg, 0.43 mmol, 1 eq), following the general 
demethylation procedure. The crude product was purified as previously described, to 
obtain the pure product with Y= 38%.   
1H NMR (400 MHz, DMSO-d6) δ  10.21 (s, OH, exchange with D2O), 9.97 (s, OH, 
exchange with D2O), 9.93 (s, OH, exchange with D2O), 9.51 (s, OH, exchange with 
D2O), 8.80 (d, J = 9 Hz, 1 H), 7.28 (s, 1H), 6.75 (dd, J = 2.2, 9.0 Hz, 1 H), 6.67 (d, J = 
1.8 Hz, 1 H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 160.74, 157.30, 150.68, 145.27, 
142.52, 140.30, 128.02, 116.00, 112.01, 110.63, 110.23, 106.82, 102.57 ppm; MS (ES): 
m/z 261 [M + H]+, 283 [M + Na]+. HPLC tR = 4.76 min, purity ≥ 99.5%. 
 
8,9,10-trihydroxy-6H-benzo[c]chromen-6-one 26 
The compound was obtained starting from 8,9,10-trimethoxy-6H-
benzo[c]chromen-6-one 25a (100 mg, 0.35 mmol, 1 eq), following the 
general demethylation procedure. The crude product was purified via 
C18 silica gel reverse phase column chromatography (H2O/MeOH/HCOOH elution 
gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to obtain an off white solid (74 mg, 
0.30 mmol). Y= 87%. 1H NMR (400 MHz, DMSO-d6) δ 10.40 (br, OH), 10.03 (br, 
OH), 9.74 (br, OH), 9.01 (d, J = 7.7 Hz, 1H), 7.45 – 7.23 (m, 4H) ppm. 13C NMR (100 
MHz, DMSO-d6) δ 160.42, 149.28, 146.38, 143.78, 140.25, 127.83, 126.87, 124.02, 
118.59, 116.46, 114.78, 112.11, 107.16 ppm; MS (ES): m/z 245 [M + H]+, 267 [M + 
Na]+. 
 
8,9,10-trihydroxy-3-phenyl-6H-benzo[c]chromen-6-one 27  
The compound was obtained starting from 8,9,10-trimethoxy-3-
phenyl-6H-benzo[c]chromen-6-one 25b (100 mg, 0.28 mmol, 1 
eq), following the general demethylation procedure. The crude 
67 
 
product was purified via C18 silica gel reverse phase column chromatography 
(H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to 
obtain a beige solid (56 mg, 0.17 mmol, 1 eq). Y= 62%. 1H NMR (400 MHz, DMSO-
d6) δ 10.43 (s, OH), 10.05 (s, OH), 9.80 (s, OH), 9.06 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 
7.3 Hz, 2H), 7.69 – 7.61 (m, 2H), 7.49 (t, J = 7.6 Hz, 2H), 7.41 (d, J = 7.2 Hz, 1H), 7.37 
(s, 1H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 160.50, 149.84, 146.49, 143.79, 
140.28, 139.35, 138.60, 129.02, 127.96, 127.92, 127.38, 126.63, 122.22, 119.50, 
117.73, 114.68, 114.02, 112.03, 107.27 ppm; MS (ES): m/z 321 [M + H]+, 343 [M + 
Na]+. 
 
2-chloro-3,8,9,10-tetrahydroxy-6H-benzo[c]chromen-6-one 28  
The compound was obtained starting from 2-chloro-3,8,9,10-
tetramethoxy-6H-benzo[c]chromen-6-one 25c (250 mg, 0.71 
mmol, 1 eq), following the general demethylation procedure. The 
crude product was purified via C18 silica gel reverse phase 
column chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio 
to a 30/70/0.1 ratio) to obtain a white solid (111 mg, 0.38 mmol). Y= 53%. 1H NMR 
(400 MHz, DMSO-d6) δ 10.71 (br, OH), 10.05 (br, 3OH), 8.94 (s, 1H), 7.29 (s, 1H), 
6.88 (s, 1H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 160.34, 152.49, 149.08, 145.81, 
142.64, 140.55, 127.31, 115.55, 114.61, 111.20, 109.56, 107.03, 103.85 ppm. 
 
2-fluoro-3,8,9,10-tetrahydroxy-6H-benzo[c]chromen-6-one 29  
The compound was obtained starting from 4-fluoro-3,8,9,10-
tetramethoxy-6H-benzo[c]chromen-6-one 25d (300 mg, 0.89 mmol, 
1 eq), following the general demethylation procedure. The crude 
product was purified via C18 silica gel reverse phase column 
chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 
30/70/0.1 ratio) to obtain  an off white solid (80 mg, 0.29 mmol). Y= 32%. 1H NMR 
(400 MHz, DMSO-d6) δ 10.41 (br, 2H), 10.00 (br, 2H), 8.68 (d, 3J H-F= 14.0 Hz, 1H), 
7.29 (s, 1H), 6.87 (d, 4J H-F= 8.0 Hz, 1H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 
160.53, 148.49, 146.16, 145.84, 144.73 (d, JC-F= 14.6 Hz), 142.55, 140.36, 115.1, 
113.25 (d, JC-F = 23.8 Hz), 110.79, 109.79 (d, JC-F= 8.4 Hz), 107.00, 104.95 (d, JC-F= 3.4 
Hz) ppm. 
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8,9,10-trihydroxy-3-(trifluoromethyl)-6H-benzo[c]chromen-6-one 30 
The compound was obtained starting from 8,9,10-trimethoxy-3-
(trifluoromethyl)-6H-benzo[c]chromen-6-one 25e (300 mg, 0.85 
mmol, 1 eq), following the general demethylation procedure. The 
crude product was purified via C18 silica gel reverse phase 
column chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio 
to a 30/70/0.1 ratio) to obtain a white solid (256 mg, 0.82 mmol). Y= 97%. 1H NMR 
(400 MHz, DMSO-d6) δ 10.58 (br,OH), 10.15 (br, OH), 10.04 (br, OH), 9.19 (d, J = 8.5 
Hz, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.39 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 
159.81, 149.06, 147.35, 144.49, 140.38, 127.71, 127.44 (d, J = 32.7 Hz), 125.07, 
122.36, 120.38 (d, J = 3.8 Hz), 113.51 (d, J = 4.1 Hz), 113.28, 112.52, 107.55. 
 
8,9-dihydroxy-10-methoxy-6-oxo-6H-benzo[c]chromene-3-carbonitrile 31 
The compound was obtained starting from 8,9,10-trimethoxy-6-
oxo-6H-benzo[c]chromene-3-carbonitrile 25f (140 mg, 0.45 mmol, 
1 eq), following the general demethylation procedure. The crude 
product was purified via silica gel column chromatography 
(DCM/MeOH 70/30 ratio) to obtain the pure product as white solid (20 mg, 0.07 
mmol). Y=16%.  1H NMR (400 MHz, DMSO-d6) δ 8.91 (d, J = 8.6 Hz, 1H), 7.94 (d, J 
= 1.6 Hz, 1H), 7.77 (dd, J = 8.5, 1.7 Hz, 1H), 7.55 (s, 1H), 3.86 (s, 3H) ppm; 13C NMR 
(101 MHz, DMSO-d6) δ 159.26, 149.38, 149.20, 146.90, 145.62, 127.94, 126.90, 
122.31, 120.84, 118.60, 118.12, 112.48, 111.21, 110.25, 59.60 ppm. 
 
1,2,3,8-tetrahydroxy-6H-benzo[c]chromen-6-one 32 
The compound was obtained starting from 1,2,3,8-tetramethoxy-
6H-benzo[c]chromen-6-one 25g (70 mg, 0.22 mmol, 1 eq), 
following the general demethylation procedure. The crude product 
was purified via C18 silica gel reverse phase column 
chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 
30/70/0.1 ratio) to obtain a brown solid (20 mg, 0.08 mmol), Y= 35%.1H NMR (400 
MHz, CD3OD) δ 8.97 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 2.8 Hz, 1H), 7.26 (dd, J = 9.0, 
2.8 Hz, 1H), 6.39 (s, 1H). 13C NMR (100 MHz, CD3OD) δ 164.12, 157.37, 147.87, 
146.01, 145.67, 129.70, 129.32, 124.46, 121.53, 114.79, 111.45, 101.29, 95.80 ppm. 
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4,4',5,6-tetrahydroxybiphenyl-2-carboxylic acid 33 
The compound was obtained starting from 4,4',5,6-
tetramethoxybiphenyl-2-carboxylic acid 24 (160 mg, 0.50 mmol, 1 
eq), following the general demethylation procedure. The crude 
product was purified via C18 silica gel reverse phase column 
chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 
30/70/0.1 ratio) to obtain a light brown solid (55 mg, 0.21 mmol). Y= 42%. 1H NMR 
(400 MHz, DMSO-d6) δ 11.76 (br, OH), 9.34 (br, OH), 9.15 (br, OH), 8.92 (br, OH), 
8.02 (br, OH), 6.91 (d, J = 8.4 Hz, 2H), 6.77 (s, 1H), 6.66 (d, J = 8.4 Hz, 2H) ppm; 13C 
NMR (100 MHz, DMSO-d6) δ 169.18, 155.55, 143.81, 143.66, 135.77, 130.88, 128.18, 
122.81, 121.62, 114.06, 108.21 ppm. 
 
phenanthrene-2,3,4,7-tetraol 35 
The compound was obtained starting from 2,3,4,7-
tetramethoxyphenanthrene 38 (63 mg, 0.21 mmol, 1 eq) following 
the general demethylation procedure. The crude product was 
purified via C18 silica gel reverse phase column chromatography (H2O/MeOH/HCOOH 
elution gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to obtain a grey solid (44 
mg, 0.18 mmol). Y= 86%. 1H NMR (400 MHz, DMSO-d6) δ  9.65 (br, OH), 9. 42 (br, 
OH) 9.42 (d, J = 9.2 Hz, 1H), 8.94 (br, OH), 8.87 (br, OH), 7.40 (d, J = 8.8 Hz, 1H), 
7.33 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 2.3 Hz, 1H), 7.02 (dd, J = 9.2, 2.6 Hz, 1H), 6.79 (s, 
1H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 153.99, 144.84, 143.25, 132.77, 132.73, 
128.63, 126.86, 125.30, 123.83, 123.52, 115.64, 113.60, 110.92, 103.81 ppm; MS (ES): 
m/z 243 [M + H]+, 265 [M + Na]+. 
 
3,8,10-trihydroxy-6H-benzo[c]chromen-6-one 39 (UM7) 
The compound was obtained starting from 3,8,10-trimethoxy-6H-
benzo[c]chromen-6-one 25h (145 mg, 0.51 mmol, 1 eq), following 
the general demethylation procedure. The crude product was 
purified via C18 silica gel reverse phase column chromatography 
(H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to 
obtain a light yellow solid (100 mg, 0.41 mmol). Y= 80%. 1H NMR (400 MHz, DMSO-
d6) δ 10.78 (br, OH), 10.03 (br, OH), 9.99 (br, OH), 8.74 (d, J = 9.0 Hz, 1H), 7.13 (d, J 
= 2.5 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.76 (dd, J = 9.0, 2.5 Hz, 1H), 6.70 (d, J = 2.5 
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Hz, 1H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 160.78, 157.28, 156.99, 156.06, 
150.23, 128.01, 121.64, 114.78, 112.36, 109.93, 109.63, 106.01, 102.65 ppm. 
 
1,3,8-trihydroxy-6H-benzo[c]chromen-6-one 43  
The product was obtained starting from 1,3-dihydroxy-8-methoxy-
6H-benzo[c]chromen-6-one 46a (250 mg, 0.968 mmol), following 
the demethylation general procedure. The crude product was 
purified via C18 silica gel reverse phase column chromatography 
(H2O/MeOH/HCOOH elution gradient 60/40/0.1 ratio) to obtain a yellow powder (80 
mg, 0.33 mmol). Y= 34%. 1H NMR (400 MHz, DMSO-d6) δ 10.71 (br, OH), 10.03 (br, 
2OH), 8.82 (d, J = 9.0 Hz, 1H), 7.53 (d, J = 2.8 Hz, 1H), 7.27 (dd, J = 9.0, 2.6 Hz, 1H), 
6.37 (d, J = 2.2 Hz, 1H), 6.23 (d, J = 2.1 Hz, 1H) ppm; 13C NMR (100 MHz, DMSO-d6) 
δ 160.70, 157.9, 156.6, 155.7, 152.2, 127.8, 127.2, 123.5, 119.8, 113.5, 99.7, 99.0, 
94.82 ppm.    
 
phenanthrene-2,4,7-triol 50 
The compound was obtained starting from 2,4,7-
trimethoxyphenanthrene 53 (200 mg, 0.75 mmol, 1 eq), following 
the general demethylation procedure. The crude product was 
purified via C18 silica gel reverse phase column chromatography (H2O/MeOH/HCOOH 
elution gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) to obtain a brown solid (17 
mg, 0.08 mmol). Y= 10%. 1H NMR (400 MHz, DMSO-d6) δ 10.34 (br, OH), 9.48 (br, 
2OH), 9.37 (d, J = 9.2 Hz, 1H), 7.48-7.43 (m, 2H), 7.11 (d, J = 2.4 Hz, 1H), 7.04 (dd, J 
= 9.2, 2.5 Hz, 1H), 6.68 (s, 2H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 156.53, 
154.88, 153.95, 134.04, 132.43, 128.59, 126.95, 126.78, 123.89, 116.30, 112.86, 
111.12, 103.69, 103.08 ppm. 
 
3,4,8,10-tetrahydroxy-6H-benzo[c]chromen-6-one 54 (Uro-E) 
 The compound was obtained starting from 3,4,8,10-tetramethoxy-
6H-benzo[c]chromen-6-one 57 (50mg, 0.16 mmol, 1 eq), 
following the general demethylation procedure. The crude product 
was purified via C18 silica gel reverse phase column 
chromatography (H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 
30/70/0.1 ratio) to obtain an off white solid (28 mg, 0.11 mmol). Y= 67%. 1H NMR 
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(401 MHz, CD3OD) δ 8.38 (d, J = 9.0 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 6.80 (d, J = 2.5 
Hz, 1H), 6.76 (d, J = 9.0 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ 163.38, 158.42, 
157.88, 146.75, 140.65, 133.34, 122.95, 119.12, 117.56, 112.63, 112.53, 111.03, 107.34 
ppm. 
 
 
General procedure for the carbonyl reduction of dibenzopyranones 46a, 46b, 43 to 
dibenzopyranes 47-49. 
A cooled solution of dibenzopyranones (1 eq), in a mixture of BF3·Et2O (25 eq) in dry 
THF was added over 10 minutes to a suspension of NaBH4 (3.5 eq) in dry THF under 
nitrogen atmosphere while maintaining the reaction temperature below 10 °C. The 
reaction mixture was then raised within 30 min to the reflux temperature for 2h. The 
solvent was removed in vacuum and the crude product was dried in high vacuum to 
remove the excess of boron trifluoride etherate. Then water was added and the mixture 
extracted with diethyl ether. The combined organic phases were dried over Na2SO4, and 
the solvent evaporated in vacuum. The crude product was purified via flash silica gel 
column chromatography. 
 
8-methoxy-6H-benzo[c]chromene-1,3-diol 47 
The compound was obtained starting from 1,3-dihydroxy-8-
methoxy-6H-benzo[c]chromen-6-one 46a (800 mg, 3.1 mmol, 1 
eq) followed the general procedure for carbonyl reduction. The 
crude product was purified via flash silica gel column chromatography (DCM/MeOH 
99.5/0.5) to obtain a white solid (470 mg, 1.92 mmol). Y= 62%. 1H NMR (400 MHz, 
DMSO-d6) δ 9.84 (s, OH), 9.37 (s, OH), 8.17 (d, J = 8.7 Hz, 1H), 6.85 (dd, J = 8.8, 2.8 
Hz, 1H), 6.80 (d, J = 2.6 Hz, 1H), 6.08 (d, J = 2.4 Hz, 1H), 5.87 (d, J = 2.4 Hz, 1H), 
4.87 (s, 2H), 3.75 (s, 3H) ppm; 13C NMR (100 MHz, DMSO-d6) δ 157.4, 156.9, 156.4, 
156.1, 131.72, 126.2, 122.5, 113.2, 109.8, 102.8, 97.5, 95.4, 68.0, 55.1 ppm. 
 
6H-benzo[c]chromene-1,3-diol 48145 
The compound was obtained starting from 1,3-dihydroxy-6H-
benzo[c]chromen-6-one 46b (800 mg, 3.51 mmol, 1 eq) followed the 
general procedure for carbonyl reduction. The crude product was 
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purified via flash silica gel column chromatography (DCM/MeOH 99/1 ratio) to obtain 
a white solid (170 mg, 0.79 mmol). Y= 23%. 1H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 
OH), 9.53 (s, OH), 8.25 (d, J = 7.9 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.19-7.12 (m, 2H), 
6.11 (d, J = 2.3 Hz, 1H), 5.89 (d, J = 2.3 Hz, 1H), 4.90 (s, 2H) ppm; 13C NMR (100 
MHz, DMSO-d6) δ 158.3, 157.3, 156.8, 130.0, 129.8, 127.7, 125.1, 124.8, 124.2, 102.8, 
97.5, 95.4, 67.9 ppm. 
 
6H-benzo[c]chromene-1,3,8-triol 49 
The compound was obtained starting from  1,3,8-trihydroxy-6H-
benzo[c]chromen-6-one 43 (190 mg, 0.78 mmol, 1 eq) following 
the general procedure for carbonyl reduction. The crude product 
was purified via flash silica gel column chromatography (DCM/MeOH 99.3/0.7) to 
obtain a white solid (30 mg, 0.13 mmol). Y= 17%. 1H NMR (400 MHz, CD3OD) δ 8.16 
(d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6, 2.5 Hz, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.04 (d, J = 
2.0 Hz, 1H), 5.94 (d, J = 2.0 Hz, 1H), 4.83 (s, 2H) ppm; 13C NMR (100 MHz, CD3OD) 
δ 158.2, 158.1, 157.2, 156.3, 133.5, 128.0, 123.1, 115.5, 111.8, 105.4, 98.50, 96.7, 69.8 
ppm. 
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Part II 
TOWARDS THE DEVELOPMENT OF FLUORESCENT AND 
AFFINITY PROBES TO INVESTIGATE NEUROGENESIS 
 
1.  Introduction 
1.1 Project overview 
This part deals with the research activity carried out during the six-month placement 
under the supervision of Professor Angela Russell at Chemistry Research Laboratory, 
Department of Chemistry, University of Oxford, part-funded by and in collaboration 
with the spin-out company OxStem Neuro.  
The present project, in collaboration with Professor Francis Szele (Department of 
Physiology, Anatomy and Genetics, University of Oxford) focused on the development 
of small molecules as affinity and fluorescent probes to detect new pathways involved 
in neurogenesis and Neural Stem Cell (NSC) fate.    
 
1.2 Opportunities for neurodegenerative diseases: regenerative 
medicine 
Age related neurological diseases are estimated to affect as many as a billion people 
worldwide and with the growth of the aging population and increasing life expectancy, 
are predicted to increase 12% by 2030 (World Health Organization 2006). These 
disorders include Parkinson and Alzheimer’s diseases, less common conditions such as 
motor neuron disease, multiple sclerosis and rare diseases such as spinal muscular 
atrophy. There are also numerous psychiatric conditions that may involve neuronal 
damage. 
A common hallmark of neurodegenerative diseases is the progressive loss of neurons 
and other brain cells.147 Currently, treatment for these disorders are limited and aims to 
treat the symptoms, but are not effective to slow or stop the neuronal death process. The 
development of disease-modifying therapies has been slower and there is a pressing 
need for improved and novel therapeutic approaches to treat these disorders.148,149 
     Emerging therapeutic opportunities arise from regenerative medicine that involves 
methods to replace or regenerate human cells, tissues or organs in order to restore or 
74 
 
establish normal function; it is founded on the possibility to exploit stem and progenitor 
cells, which have the capacity for self-renewal and differentiation to various cell 
lineages.150,151 
In recent years a number of treatment options have been investigated, including cell 
therapy and tissue engineering.152 A diverse and innovative regenerative approach, that 
led medicinal chemistry to play a pivotal role in this field, is the Endogenous Cell 
Activation Therapy (ECAT), that is based on the in situ modulation of adult stem or 
precursor cells using small molecules, to induce regeneration or repair of adult 
tissue.153,154 (Figure 19) 
 
 
 
Figure 19. Regenerative medicine approaches: cell transplantation and tissue engineering vs ECAT 
(Image from http://www.oxstem.co.uk/stem-cells/oxstem-approach). 
 
The potential of small molecules to control stem cell fate has been deeply investigated 
in the literature.155–157 ECAT can offer significant advantages over cell therapy, in term 
of reduced costs and risks, and also for its ability to control cell fate reversibly.158,159 
Therefore, the search for drugs that target endogenous stem cell populations in vivo to 
stimulate repair and regeneration processes is actively pursued and represent a powerful 
application of regenerative medicine, elegantly defined by A. Russell as “regenerative 
medicinal chemistry”.158 Recent years have seen the enter in clinical use of  the first 
small molecule regenerative drug acting in situ on resident progenitor cells 
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(eltromboplag, FDA first approved 2008) and many other agents are in preclinical and 
clinical development, the majority of which targeting the hematopoietic stem cells. 
Interest in this direction is expanding also for the treatment of other disorders with high 
unmet medical need, among which neurodegenerative diseases.153 
     In the adult brain, functional neurons and other brain cells are generated from neural 
stem cells (NSCs) and neural precursor cells (NPCs) in a process called 
neurogenesis.160–162 
The discovery of adult neurogenesis has sparked optimism that this endogenous process 
can be harnessed to repair the injured or diseased brain, offering great promise for 
treating neurodegenerative diseases.163,164 
Over the past five decades, adult neurogenesis and NSCs have been deeply investigated: 
pioneers works focused on characterizing the process of adult neurogenesis165–168 were 
followed by efforts to understand its molecular mechanism and functional 
significance.163,169,170 Current research in the field continues to study NSC regulatory 
mechanisms in an effort to take advantage of the regenerative capacity of adult NSCs: a 
deeper understanding of the processes underlying adult neurogenesis and its function in 
the mammalian brain may lead to new potential therapeutic targets for stimulating 
neurogenesis and contribute to regenerative approaches for treating neurological 
diseases.171 
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1.3 NSCs and neurogenesis in the adult mammalian brain  
Adult neurogenesis is the process of generating neurons and glial cells from neural 
precursors, NSCs and NPCs, and occurs throughout life in restricted brain regions in 
mammals.163,172,173  
NSCs are multipotent stem cells characterized by the properties of self renewal and 
differentiation. They can generate three cell types: neurons, astrocytes and 
oligodendrocytes (Figure 20).174 
 
  
Figure 20. Schematic diagram illustrating potential behavior of adult NSC over its life cycle. 
 
Interestingly, astrocytes release factors that induce neuronal differentiation.175 NSCs 
reside within specific environment, or “niche”. The two major niches in the adult 
mammalian brain are the subventricular zone (SVZ) lining the lateral ventricles and the 
subgranular zone (SGZ) within the dentate gyrus (DG) of the hippocampus (Figure 
21).163,174 
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Figure 21. Schematic illustration of the NSCs nests in the brain: SVZ and DG. 
 
Particularly, neurogenesis in the dentate gyrus (DG) of the hippocampus has been 
robustly demonstrated in adult rodents and has also been observed in sheep, non- human 
primates, and humans.168,176 A comparison study of the two neurogenic niches in 
humans has been reported.177 
 Embryonic stem cell-derived NSCs cultured in vitro, in the presence of defined growth 
factor generate all three brain cell types, however several studies have shown that they 
are more lineage restricted in vivo;178–180 we can reasonable affirm that adult NSCs are 
intrinsically tri-potent, but the in vivo niche in which they reside may limit the adult 
NSC potential.  
Understand and manipulate the molecular signalling pathways that control NSC features 
such as activation, fate specification and lineage restriction in the brain is currently 
under active investigation. 
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    1.3.1 Adult neurogenesis regulation  
Adult neurogenesis is a dynamic, finely tuned process regulated by both intrinsic and 
extrinsic factors (Figure 22).171,174  
Intrinsic factors are the intracellular regulators: epigenetic modifications, cell cycle 
regulators, transcription factors. Extrinsic factors are the extracellular component that 
constitutes the niche microenvironment in which NSCs reside: morphogens (Notch, 
Sonic Hedgehog, Wnts), hormones, cytokines, neurotrophines, growth factors, 
neurotransmitters.169 
 
 
Figure 22. Schematic illustration of intrinsic and extrinsic mechanisms that regulate adult NSCs.174 
 
Signaling mechanisms, including morphogens, growth and neurotrophic factors, 
neurotransmitters, transcription factors, epigenetic modulators interact with each other 
in the regulation of NSCs and adult neurogenesis.170 
Moreover, adult neurogenesis is subject to modulation by various physiological, 
pathological, and pharmacological stimuli, including exercise, aging, stress and 
disease.169,181 
Finally, it is worth noting that numerous studies have reported alterations in adult 
neurogenesis that are associated with several neurological and psychiatric disorders, 
providing a link between adult neurogenesis and human disease.182 
This provides a further evidence that stimulating neurogenesis represent a promising 
approach in the search for effective therapies in such diseases. 
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     It is clear that every single phase of adult neurogenesis can be regulated by different 
stimuli and different stimuli interact with each other, affecting the final outcome of 
adult neurogenesis. The major challenge is to identify cellular and molecular 
mechanisms underlying adult neurogenesis regulation.  
     Importantly, small molecules can stimulate NSC-mediated neurogenesis through one 
or more mechanisms, including direct targeting stem cells and interference with 
mediators of the niche. 
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1.4 Therapeutic application of NSCs: from cell therapy to small 
molecules 
The self-renewing and multipotent properties of NSCs in the adult brain can be 
exploited to replace damage neurons with functioning, normal ones according to the 
principles of the regenerative medicine. 
Manipulation of NSCs and NPCs in vitro for stem cell therapy approaches, involving ex 
vivo stimulation and differentiation followed by transplantation into the patient, have 
been explored. Clinical trials using NSCs are under investigation for spinal cord injury, 
macular degeneration and amyotrophic lateral sclerosis (US National Institute of Health 
clinical trials database). However, clinical applications of NSCs based on cell therapy 
has shown limited success due to several unsolved problems such as increased risks of 
tumorigenicity and immune rejection.183 
On the contrary, the in situ modulation of NSCs by small molecules, (ECAT, endogenous 
cell activation therapy), is considered more clinically acceptable; indeed it would be 
without immunogenicity problems, and also evades the need for invasive surgery. 
Moreover, the identification of small molecules acting on neurogenesis is particularly 
attractive because they can serve as tools to investigate the mechanisms of 
neurogenesis. 
 
   1.4.1 Small molecules promoting neurogenesis 
Several solid lines of evidences show that drugs and drug-like molecules can stimulate 
NSC- mediated neurogenesis. In Figure 23 some examples are reported. 
All-trans retinoic acid (ATRA, 58) is one of the first molecules known to induce 
neurogenesis in vitro,184 thus is widely used as reference compound in the search for 
proneurogenic small molecules.  
Antidepressants currently on the market from multiple mechanistic classes, including 
fluoxetine 59, imipramine 60, have been shown to induce neurogenesis in vitro and in 
vivo.185,186 Even if the association between neurogenesis and antidepressant action 
remains controversial, they might exert some or all of their effects by promoting 
neurogenesis.187  
Increased hippocampal neurogenesis was also observed in vivo in rat treated with 
dehydroepiandrosterone (DHEA, 61),188 pregnenolone 189 or allopregnanolone 62.190  
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Triazinone molecule 63 showed to enhance neurogenesis in the hippocampus through a 
multi-target approach of β-secretase and GSK-3β inhibition.191 
Recently an orally active neurogenic small molecule, NSI-189 (64), entered in a clinical 
trial as anti-depressant drug192 and is progressing Phase 2 efficacy trial 
(ClinicalTrials.gov, 2016, Identifier: NCT02695472) for treatment of major depression. 
In another study, NSI-189 showed to enhance cell proliferation and neurogenesis in a 
rat model of ischemic stroke.193 Until now, the mechanism of action mediating the 
neurogenic effects of NSI-189 remain elusive. 
Other examples of drug-like molecules promoting neurogenesis have been 
described.153,154 
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Figure 23. ATRA (58) and examples of recently discovered proneurogenic small molecules 59-64. 
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2. Aim of the work  
In this context, one of the goals of Professor Angela Russell’s Group is to find 
proneurogenic compounds and to understand the mechanism through which they 
stimulate neurogenesis. 
For this purpose, through a collaboration with the group of Professor Francis Szele, they 
have developed screening models able to identify new small molecules promoting 
neurogenesis in vitro and in vivo. 
In a first screening, 1500 compounds (Mix of GSK-3β inhibitors and structurally 
diverse drug-like molecules) were tested in vitro on murine-derived NSCs to assess the 
effect on neurogenesis via immunohistochemistry (Figure 24). The percentage of neurons 
against the total number of nuclei was calculated. (See Appendix B) 
 
 
Figure 24. Initial screening carried out by Dr. Julie Davies (DPAG, University of Oxford). 
 
From the initial screening, a number of compounds resulted active (hit identification), 
thus following a common drug discovery approach (Figure 25), they were 
resynthesized and retested in in vitro assays to confirm biological activity, according to 
the hit validation process. Some of the validated hit are progressing the hit to lead 
optimisation, to improve pharmacokinetic profile and to explore structure-activity 
relationships (SAR). (Figure 25) 
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Figure 25. Drug discovery process in the search for proneurogenic compounds. 
 
Among the first validated hits, OX02672 (65) (Figure 26a) (The structure of OX02672 
can not be disclosed yet. Indeed, the work is still in progress and it is going to be 
submitted for patenting) showed a good dose-dependent increase in neurogenesis in 
both the DG-derived NSCs and SVZ-derived NSCs (Figure 26b). Pharmacokinetics 
(PK) studies and in vivo efficacy studies (wild tipe mice) were also performed. From 
preliminary data, compound OX02672 (65) showed a significant increase of 
neurogenesis in vivo in the DG. (Figure 26c). 
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Figure 26. a) OX02672 (65) Masked structure. b) Dose dependent increases in neurogenesis from NSC’s 
isolated from DG and SVZ. (Asterisks indicate significance when compared to DMSO. *P< 0.05. **P< 
0.01). c) Quantification of BrdU/NeuN positive cells in the DG. Tests were carried out by Dr Julie Davies 
(DPAG, University of Oxford). For more details, see Appendix B. 
 
While this compound requires further optimisation to be considered as a lead 
compound, its good activity in vitro and in vivo made it a useful tool compound for 
chemical biology investigations. 
    Since its proneurogenic activity was discovered from a NSC-based phenotypic assay, 
OX02672 acts through, as yet, unknown mechanism. Therefore, it represents a useful 
tool to investigate pathways involved in neurogenesis and NSC specification. 
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    2.1 Development of OX02672 as fluorescent and affinity probe for 
chemical proteomics 
On these premises, my work aims to use a chemical biology approach to develop 
OX02672 into affinity and fluorescent probe to be used in chemical proteomics to 
assess its molecular interactions and localization in NSCs.    
Chemical proteomics uses chemically synthesized molecular probes usually coupled 
with high-resolution detection methods such as mass spectroscopy (MS) for the study of 
small molecule–protein interactions.194 The Activity-Based Protein Profiling (ABPP) 
approach in particular has been successfully used for target identification of drugs and 
other bioactive small molecules.195–197  Chemical probes for ABPP (activity-based 
probes, ABP) are generally composed of a reactive group (the bioactive compound) for 
binding or modifying the target proteins and a reporter tag for the identification and 
purification of binding proteins. (Figure 27a) 
There are two types of reporter: (i) fluorophores, such as rhodamine, for visualization 
by in-gel fluorescence coupled with SDS-PAGE to visualize binding proteins; (ii) 
affinity tags, such as biotin, for both western blot analysis and avidin enrichment prior 
to mass-spectrometry (MS)-based identification.198  
Classical ABPP methods (Figure 27b) present some limitations: the conjugation with 
the tag can significant alter the structure of the original bioactive small molecule; most 
ABP have limited cell permeability due to their bulky reporter tag; ABPP experiments 
are conducted almost exclusively with cell and tissue homogenates. 
It would be an ideal strategy one that can faithfully recapitulate protein-small molecule 
interactions in situ (e.g. in living cells).199,200 
Among in situ methods for cell-based proteome profiling of small molecules, “click 
chemistry ABPP” (Figure 27c) is based on “clickable” chemical probes: the original 
bioactive compound is modified through the introduction of a chemically ‘tractable’ tag; 
the tag must minimally disrupt protein–ligand interaction in situ, and provide a handle 
for subsequent in vitro protein enrichment and other proteomic applications. A terminal 
alkyne is a tag-of-choice because it is small and can be easily conjugated with high 
efficiency with azide-containing reporters through a click chemistry reaction, such as 
the copper-catalyzed azide–alkyne 1,3-dipolar cycloaddition (CuAAC).201–204   
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Figure 27. a) Activity based probe general structure (ABP); b) Classical ABPP; c) Click chemistry 
ABPP. (Adapted from Martell et al.201)  
 
Alkyne-tagged probes (Figure 27c) can be considered “in-cell small molecule clickable 
probes”: they first interact with the protein target(s) in cells or in vivo, then the 
bioorthogonal reaction CuAAC can be performed in living cells or ex vivo, allowing the 
in situ attachment of the reporter. Ghosh and Jones reviewed the use of small molecule 
imaging probes that rely on a click handle to which a fluorescent dye can be appended 
intracellularly.205 
 
    2.2 Chemistry  
Following the click ABPP approach, cell permeable OX02672 probes containing a 
terminal alkyne tag have been designed. Then, CuAAC of some of the synthesized 
probes was performed, with simple azide and with a fluorescent dye, to prove the good 
reactivity of the new probes in the click reaction. 
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While the synthetic transformations can be discussed, the structures of the new 
derivatives can not be disclosed yet. Indeed, the work is still in progress and it is going 
to be submitted for patenting. 
The first thing to consider in the design of a probe is the SAR assessment: thus, in order 
to identify where a tag could be appended while retaining the activity, a number of 
analogues of 65 modifying the 1, 2 and 3 positions were synthesized and submitted to 
biological evaluation by some member of the group.  
In particular, the present work focused on the synthesis of some analogues (66-68) of 65 
to expand SAR on the position 1, and mostly on the synthesis of the alkyne-tagged 
analogues 69-74 for probes development, modifying all the three positions, since the 
SAR of 65 were not yet determined. (Figure 28) 
 
 
Figure 28. New analogues 66-68 for SAR studies and alkyne tagged derivatives 69-74 for probes 
development. 
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The synthesis of analogues 66-68 is shown in Scheme 12. Suzuki coupling was 
performed on compound 65 with three different boronic acids 75-77 to obtain 
methoxyphenyl- 66, benzyloxyphenyl- 67 and phenol- 68 derivatives, respectively, with 
very good yields. 
 
Scheme 12. Synthesis of derivatives 66-68 
  
Then, derivative 68 through alkylation with propargyl bromide, using K2CO3 as base, 
gave the alkyne derivative 69 as shown in Scheme 13. 
 
Scheme 13. Synthesis alkyne derivative 69 
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Compound 70 (Scheme 14B) was obtained through microwave-assisted regioselective 
nucleophilic substitution starting from  the dibromoderivative 75 and the synthesized 
amine 78, in analogy to the synthesis of the parent compound 65, showed in Scheme 
14A. The amino alcohol 78 was obtained from the commercially available chiral amino 
acid 77 through reduction of the acid function with LiAlH4. 
 
Scheme 14. A) synthesis of OX02672 (65) and (B) Synthesis of derivative 70 
 
 
Synthesis of derivatives 71-74 is shown in Scheme 15. Through coupling reaction of 65 
with commercial acid 79 in presence of EDC and DMAP, ester derivative 71 was 
obtained in very good yield. 
To obtain the alkylated derivative 72-74, alkylation reactions were performed with 
propargyl bromide and 4-bromo-1-butyne, KOH as base and DMF as solvent, varying 
the reaction condition as described in Table 3. 
In presence of 1.5 eq of propargyl bromide and 1 eq of base at 35 °C, the alkylation of 
65 occurred on the alcohol group in position 2 to give compound 72 (entry 1). 
Increasing the equivalent amounts of propargyl bromide and base, and the temperature, 
a mixture of alkylated derivatives 72 and 73 (derivative alkylated on the amine in 
position 3) was obtained (entry 2). Alkylation with 4-bromo-1-butyne occurred with 
excess of reagents at higher temperature to give 74, the derivative alkylated on the 
amine in position 3 (entry 3). 
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Scheme 15. Synthesis alkyne analogues 71-74 
 
 
Table 3. Alkylation reaction conditions to obtain compounds 72-74 
entry n Bromide eq KOH eq T t Product (Y) 
1 1 1.5 1 35 °C 12h 72 (13%) 
2 1 3 3 60 °C 24h 72 (10%) + 73 (10%) 
3 2 3 3 110 °C 20h 74 (10%) 
 
 
All the new derivatives were characterised with 1H-NMR, 13C-NMR, IR spectroscopy 
and HRMS spectrometry; COSY, HSQC, HMBC and NOESY experiments were also 
performed when needed. 
All the new derivatives were submitted to the biological evaluation to assess their 
proneurogenic activity, in order to gain information on the SAR of 65 and to decide 
which alkyne derivatives can progress in the probe development. 
    Finally, click reaction on some alkyne-probes was performed with simple azide and 
with a fluorescent dye (Scheme 16) to check if the compounds have a good reactivity in 
the CuAAC. 
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Not knowing yet which derivative maintains the bioactivity of the parent compound, we 
chose derivatives 72 and 70 to perform CuAAC with the commercial benzyl azide (1 
eq) to assess the reaction conditions, obtaining the triazoles derivatives 80 and 81. Then, 
the derivative 70 was chosen as the structurally closest analogue to the parent 
compound to perform the click reaction with the rhodamine azide derivative 82 
obtaining the potentially useful fluorescent probe 83, which was characterised by 1H-
NMR, 13C-NMR and HRMS. 
 
Scheme 16. Click chemistry reaction 
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3. Conclusions  
In my six-month placement carried out under the supervision of Professor Angela 
Russell at Department of Chemistry (University of Oxford) my work aimed, through a 
chemical biology approach, on  the development of small molecules as affinity and 
fluorescent probes to detect new pathways involved in neurogenesis and Neural Stem 
Cell (NSC) fate.    
A series of different substitued and alkyne-tagged derivatives of the recently discovered 
proneurogenic compound OX02672 (65) have been synthesized and submitted for the 
biological evaluation.  
Some of the alkyne-tagged analogs were «clicked» with a simple azide and a 
rhodamine-azide-derivative through click chemistry, proving this strategy can be useful 
for the further development of 65 into fluorescent probe.  
Moreover, the alkyne-tagged derivatives which will show to maintain the bioactivity of 
the parent compound could be developed as diverse fluorescent probes (using different 
fluorophores) and also as affinity probes by bioconjugation with a biotin-azide-
derivative in the click reaction. Then they can be  used in chemical proteomics and other 
target identification in situ methods. 
These studies may serve to assess the localization in NSCs and their progeny and to 
identify the target protein(s). This in turn may help to understand the mechanism of 
action of this proneurogenic compound and to gain a better knowledge of the signaling 
pathways that control adult neurogenesis, finally supporting the development of drugs 
that stimulate de novo neurogenesis for the treatment of central nervous system 
diseases. 
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 Part III 
DESIGN AND SYNTHESIS OF TACRINE-RESVERATROL FUSED 
HYBRIDS AS MULTI-TARGET-DIRECTED LIGANDS AGAINST 
ALZHEIMER'S DISEASE 
 
1.Introduction 
    1.1 Project overview 
This last section describes a side project carried out in collaboration with the groups of 
Professor Maria Laura Bolognesi and Professor Jan Korabecný of Prague University, 
aimed to the identification of a new series of multi-target-directed ligands (MTDLs) 
against Alzheimer's disease (AD).206 
 
    1.2 Multi-target drug discovery in Alzheimer disease 
One of the most followed approaches in the central nervous system (CNS) therapeutic 
area is multi-target drug discovery, especially in the search for new drugs against AD.207 
This is because multi-target-directed ligands (MTDLs) could more adequately address 
the complexity of this pathological condition, since they have the potential to promote a 
number of goals including (i) an inherently higher adequateness to confront the complex 
AD pathogenesis; (ii) a larger therapeutic window; and (iii) a simplified therapeutic 
regimen.208 
Several promising anti-AD MTDLs have been reported;209,210 however, no one has 
progressed to clinical development.211 Thus, there is still a need for novel MTDLs 
potential useful as anti-AD drug candidates. 
    Molecular hybridization has been the most widely applied design strategy towards 
new MTDLs for AD.212 In these context, acetylcholinesterase (AChE) inhibitor tacrine, 
(84, Figure 29) has been used as starting scaffold to obtain molecular hybrids with 
improved biological profiles,213 particularly its derivatives, the more potent 6-
chlorotacrine 85214  and the less hepatotoxic 7-methoxytacrine 86.215 
A wide set of tacrine-based hybrids reported in the literature incorporate a fragment 
derived or inspired by a natural product.216 Indeed, natural products have intrinsic multi-
target profile, being evolutionarily selected and biologically pre-validated, therefore 
they are considered suitable starting points for the development of MTDLs against 
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AD.217 Among the natural products with therapeutic potential in the field of 
neurodegenerative diseases, resveratrol (87, Figure 29), a polyphenol mainly found in 
grapes and red wine, has attracted great attention for its beneficial effects due to its 
antioxidant and anti-inflammatory properties.218 Notably, a recent clinical trial aimed to 
evaluate the impact of resveratrol treatment in patients with mild to moderate AD.219 
 
 
Figure 29. Tacrine 84, tacrin derivatives 85-86 and resveratrol 87 structures. 
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2. Aim of the work 
On these basis, with the aim to develop a new series of anti-AD MTDLs, the 
anticholinesterase properties of 84-86 were combined with the antioxidant, 
immunomodulatory and neuroprotective framework of resveratrol 87, through the 
design of fused hybrids 88-95 (Figure 30). We reasoned that this structural 
hybridization might have positive effects in terms of neuroinflammation and safety. 
From toxicity point of view, resveratrol is known to be safe in humans219 and, 
importantly, it has demonstrated beneficial effects in animal models of hepatic insult.220  
In addition, the notion that resveratrol 87 might directly halt amyloid aggregation221 
potentially expands the therapeutic profile of the new hybrids derivatives.  
Among the molecular hybridization approaches, we choose the fusing strategy because 
in principle, a fused hybrid should possess improved drug-like features (such as 
decreased size and complexity) compared to a linked one.222 This aspect is of crucial 
importance in the design of hybrids directed to the CNS, where more stringent 
physiochemical properties are requested, particularly the hybrid must to permeate 
blood-brain-barried to exert its effect.223 
Toward the goal of a maximal structural overlap, we turned our attention to the 4’-
amino derivative of resveratrol 96, which has been reported to exert anti-aggregating, 
antioxidant and neuroprotective effects in AD cellular models.224 This allowed us to 
fuse the two structures through the common amino group (i.e. the 9-NH2 of 84-86 and 
the 4’-NH2 of 96) (Figure 30). 
 
 
Figure 30. Design strategy to tacrin-resveratrol fused hybrids. (For structures see Scheme 18). 
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A large number of anti-AD tacrine-based212,213,225–227 and resveratrol-based228–230 
hybrids have been reported. Notably, tacrine-resveratrol linked hybrids (featuring an 
alkoxy linker) have been patented as useful agents against neurodegenerative diseases, 
231
 but, to the best of our knowledge, there is no example of fused tacrine-resveratrol 
hybrids, that is the aim of the present project.  
    Retrosynthetic analysis suggested us to exploit a nucleophilic substitution between 
resveratrol amino derivatives (98-99) and 9-chlorotacrine derivatives (100-102) to 
obtain final tacrine-resveratrol fused hybrids 88-95 (Scheme 18). 
 
Scheme 17. General retrosynthetic strategy. (For structures see Scheme 18). 
 
 
 
Synthesis of hybrid compounds 88-95 is describe in Scheme 22. The key step consisted 
of a coupling between the amino-stilbene 99 or its corresponding dihydro derivative 98 
and the appropriate 9-chlorotacrines 100-102. The reaction, carried out in the presence 
of phenol under microwave irradiation and solvent free conditions, afforded the desired 
hybrid methoxylated compounds 88-90 and 92-94 in moderate to good yields (32-52%). 
The dihydroxy derivatives 91 and 95 were obtained, in 93% and 31% yield respectively, 
by demethylation of the corresponding dimethoxy hybrids 88 and 92 with boron 
tribromide at -78 °C.  
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Scheme 18. Synthesis of tacrine-resveratrol hybrids 88-95  
 
Amino derivatives 98-99 were prepared starting from the common intermediate trans-
nitro-stilbene derivative 97 as previously reported.232,233 Amino-stilbene 99232,233 was 
obtained by selective reduction of the nitro group with Tin (II) chloride, whereas the 
corresponding dihydro derivative 98234 was obtained by catalytic hydrogenation in 
continuous-flow reactor that allowed simultaneous reductions of the nitro group and the 
ethylene bridge. The 9-chlorotacrine derivatives 100-102 has been synthesized as 
previously described.235,236 
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3. Biological evaluation and discussion of results 
Biological evaluation of newly synthesized hybrids compounds was carried out by 
groups of Professors Manuela Bartolini, Barbara Monti (UniBO), and the group of 
Professor Jan Korabecny of Charles University in Prague. The biological experiment 
protocols and the in-depth analysis of biological results have been reported,206 thus only 
some relevant aspects are described in this paragraph. 
To evaluate the potential interest as MTDLs against Alzheimer disease, they were first 
tested for cholinesterase inhibition and derivatives 88, 89, 91 and 95 showed significant 
inhibitory activity with IC50 values from 0.8 to 14.2 µM (Table 4). The majority of the 
active compounds is part of the subset in which the stilbene double bond is reduced (88, 
89 and 91). Particularly, 88 is the most potent inhibitor of the series, displaying an IC50 
of 0.8 μM, which is comparable to that of reference drug tacrine 84 (IC50 = 0.5 μM). 206 
Compound 95 is the only resulted active among the hybrids featuring the double bond 
of the stilbene moiety (92-95) with an IC50 value of 8.8 µM. However, it should be 
noted that 95, together with 88 and 91, bears a 6-chlorotacrine fragment, confirming the 
essential role of this fragment in AChE recognition. 
    Since the potential of tacrin-based hybrids to act as inhibitors of amyloid aggregation 
has been widely recognised,213,225 as well as the antiaggregating properties of 
resveratrol,221 88-95 were tested for their ability to inhibit Aβ
 
self-aggregation.206 
Interestingly, the most active compounds result 91 and 95, which showed slightly 
improved Aβ aggregation inhibitory profile compared to resveratrol 87 (Table 4). 
 
Table 4. Inhibition of human AChE and Aβ Self-Aggregation of derivatives 88-95 and reference 
compounds 84–87. 
 
Compound 
IC50 ± 
SEM 
(µM) for 
Human 
AChE 
IC50 ± 
SEM 
(µM) for 
Human 
BChE 
Aß42 self-
aggregation 
% Inhibition 
[I] = 50 µM 
88 0.8 ± 0.05 n.a. 17.6 ± 1.6 
89 14.2 ± 2.9 n.a. n.d. 
90 n.a. n.a. n.d. 
99 
 
91 1.3 ± 0.1 n.a. 37.3 ± 4.1 
92 n.a. n.a. 21.6 ± 4.9 
93 n.a. n.a. n.d. 
94 n.a. n.a. n.d. 
95 8.8 ± 0.4 n.a. 31.2 ± 9.0 
84 0.5 ± 0.1a 0.023 ± 3a <5 
85 0.007 ± 
0.02a 
0.85 ± 
30.6a 
<5 
86 10.5 ± 2a 21 ± 3000a n.d. 
87 n.a.b n.a.b 30.0 ± 8.7 
n.a.- not active, no enzyme inhibition at compound’s concentration of 10 μM. 
n.d. - not determined. 
a
 Data taken from Nepovimova, E. et al.227 
b
 No inhibition observed in tested concentration up to 100 μM. 
 
    Compounds were then evaluated for neurotoxic effects on primary neurons (Figure 
31)206 and compound 95 showed no clear neurotoxicity, thus it was further investigated 
and tested in a cell model of AD neuroinflammation, where it showed anti-
inflammatory and immune-modulatory properties (data not shown).206 
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Figure 31. Neurotoxicity of 88-95 on primary rat cerebellar granule neurons (CGNs) after 24 h treatment. 
Results are expressed as percentage of controls and are the mean ± SE of four different experiments run at 
least in quadruplicate.206 
 
    Compounds were then evaluated for the antioxidant activity and hepatotoxicity (data 
not shown). Only compound 88 showed reasonable antioxidant activity, albeit lower 
than that of resveratrol.206  
The assessment of hepatotoxicity would be of critical importance for evaluating the 
drug-likeness of the newly synthesized hybrids, since the serious hepatotoxicity of 84 
limited its clinical use.225 We hypotized a lower hepatotoxicity for the hybrids 
compounds on the basis of the hepatoprotective properties of resveratrol 87,237 but 
contrary to our expectations all the compounds displayed significant hepatotoxic 
effects.206  
Importantly, preliminary evaluation through a BBB (blood-brain barrier) predictor 
server indicated high permeation properties for this series of compounds.206 
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4. Conclusions 
The side project (Part III) was based on the rational design and synthesis of a new series 
of multi-target-directed ligands (MTDLs) against Alzheimer's disease (AD). A new 
series of fused tacrin-resveratrol hybrids that showed interesting multi-target profile 
against target proteins involved in AD pathogenesis has been identified. The most 
interesting compounds (88, 91, 92 and 95) inhibited human acetylcholinesterase at 
micromolar concentrations and effectively modulated Aβ self-aggregation in vitro (91 
and 95). In addition, 95 showed anti-inflammatory and immuno-modulatory properties 
in AD cell models. However, a general hepatotoxicity is evident for all the derivatives, 
probably due to the presence of tacrin fragment. In this regard, when dealing with a 
drug discovery project one must be aware that since is not possible to a priori establish 
if a new hybrid (that is a new chemotype) can be toxic or not, toxicity issues should be 
addressed early in the discovery phase.  
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5. Experimental section 
General methods 
Reaction progress was monitored by TLC on pre-coated silica gel plates (Kieselgel 60 
F254, Merck) and visualized by UV254 light. Flash column chromatography was 
performed on silica gel (particle size 40-63 μM, Merck). If required, solvents were 
distilled prior to use. All reagents were obtained from commercial sources and used 
without further purification. When stated, reactions were carried out under an inert 
atmosphere. Reactions involving microwave irradiation were performed using a 
microwave synthesis system (CEM Discover® SP, 2.45 GHz, maximum power 300 W), 
equipped with infrared temperature measurement. Catalytic hydrogenation was 
performed on H-Cube® Continuous-flow Hydrogenation Reactor (H-Cube, ThalesNano 
Nanotechnology, Budapest, Hungary). Compounds were named relying on the naming 
algorithm developed by CambridgeSoft Corporation and used in Chem-BioDraw Ultra 
12.0. Unless state otherwise, 1H-NMR and 13C-NMR spectra were recorded on Varian 
Gemini at 400 MHz and 100 MHz respectively. Chemical shifts (δ) are reported relative 
to TMS as internal standard. Low resolution mass spectra ESI-MS were recorded on a 
Waters ZQ 4000 apparatus.  
 
Experimental procedures 
General procedure for coupling reactions (88-90 and 92-94) 
Tacrine derivatives 100-102 (1 equiv), the appropriate amine 98-99 (1-1.5 equiv) and 
phenol (4-9 equiv) were charged in a pressure tight microwave tube containing a stirring 
bar. The reaction mixture was submitted to microwave irradiation at 120 °C with an 
irradiation power of 150W for 1h. The mixture was dissolved in DCM and washed with 
sodium hydroxide 10%, brine and water, dried over sodium sulfate and evaporated. 
Crude product was purified by flash chromatography (petroleum ether/EtOAc, elution 
gradient 90:10 to 80:20). 
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6-chloro-N-(4-(3,5-dimethoxyphenethyl)phenyl)-1,2,3,4-tetrahydroacridin-9-amine 
(88) 
Coupling of compound 98 (0.270 g, 1.05 mmol) and 100 
(0.264 g, 1.05 mmol) with phenol (0.889 g, 9 equiv) was 
performed according to the general procedure described 
above. Brown solid, 0.260 g, 0.55 mmol, 52% yield. 1H 
NMR (CDCl3, 400 MHz) δ: 1.84-1.88 (m, 2H), 1.91-1.95 (m, 2H), 2.7 (t, J= 6.2 Hz, 
2H), 2.82 (s, 4H), 3.11 (t, J= 6.6 Hz, 2H), 3.75 (s, 6H), 5.93 (br, 1H, -NH-), 6.29-6.32 
(m, 3H, aromatic), 6.63 (d, J= 8.0 Hz, 2H, aromatic), 7.01 (d, J= 8.0 Hz, 2H, aromatic), 
7.21 (dd, J= 2.0 Hz, 8.8 Hz, 1H, aromatic), 7.64 (d, J= 8.8 Hz, 1H, aromatic), 7.95 (d, 
J= 1.6 Hz, 1H, aromatic), 13C NMR (CDCl3, 100 MHz) δ: 22.8, 22.9, 25.3, 34.2, 37.0, 
38.4, 55.4, 98.0, 106.7, 106.8, 115.4, 117.5, 121.0, 122.5, 125.1, 125.7, 127.8, 129.36, 
129.44, 134.5, 134.9, 142.4, 144.0, 144.3, 148.0,  160.9, 161.2; MS (ESI+): m/z: 473 [M 
+ H]+. 
 
N-(4-(3,5-dimethoxyphenethyl)phenyl)-1,2,3,4-tetrahydroacridin-9-amine (89) 
Coupling of compound 98 (0.170 g, 0.66 mmol) and 101 
(0.144 g, 0.66 mmol) with phenol (0.560 g, 9 equiv) was 
performed according to the general procedure described 
above. Yellow solid, 0.15 g, 0.34 mmol, 52% yield.  1H 
NMR (CDCl3, 400 MHz) δ: 1.85-1.88 (m, 2H), 1.93-1.99 
(m, 2H), 2.73 (t, J=6.2Hz, 2H), 2.83 (s, 4H); 3.15 (t, J= 6.4 Hz, 2H), 3.77 (s, 6H), 5.82 
(br, 1H, -NH-), 6.31-6.34 (m, 3H, aromatic), 6.64 (d, J= 8.4 Hz, 2H, aromatic), 7.02 (d, 
J= 8.0 Hz, 2H, aromatic), 7.32 (t, J= 7.6 Hz, 1H, aromatic), 7.59 (t, J= 7.6 Hz, 1H, 
aromatic), 7.76 (d, J= 8.4 Hz, 1H, aromatic), 7.98 (d, J= 8 Hz, 1H, aromatic), 13C NMR 
(CDCl3, 100 MHz) δ: 22.6, 23.0, 25.5, 34.3, 37.0, 38.5, 55.4, 98.0, 106.7, 117.1, 122.9, 
123.0, 123.3, 124.9, 128.7, 129.0, 129.3, 134.3, 142.7, 143.6, 144.4, 147.6, 160.0, 
160.9; MS (ESI+): m/z: 439 [M + H]+. 
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N-(4-(3,5-dimethoxyphenethyl)phenyl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-
amine (90) 
Coupling of compound 98 (0.100 g, 0.39 mmol) and 102 
(0.096 g, 0.39 mmol) with phenol (0.328 g, 9 equiv) was 
performed according to the general procedure described 
above. Brown solid, 0.096 g, 0.13 mmol, 33% yield. 1H 
NMR (CDCl3, 400 MHz) δ: 1.84-1.88 (m, 2H), 1.92-1.96 
(m, 2H), 2.74 (t, J= 6.4 Hz, 2H), 2.83 (s, 4H), 3.11 (t, J= 6.4 Hz, 2H), 3.66 (s, 3H), 3.77 
(s, 6H), 5.70 (br, 1H, -NH-), 6.30-6.34 (m, 3H, aromatic), 6.63 (d, J= 8.4 Hz, 2H, 
aromatic), 6.98 (d, J= 2.8 Hz, 1H, aromatic), 7.03 (d, J= 8.0 Hz, 2H, aromatic), 7.24 (m, 
1H, aromatic), 8.89 (d, J= 9.2 Hz, 1H, aromatic). 13C NMR (CDCl3, 100 MHz) δ: 22.9, 
23.1, 25.5, 33.9, 37.0, 38.5, 55.38, 55.44, 98.0, 101.8, 106.7, 117.0, 121.3, 123.4, 123.8, 
129.3, 130.4, 134.1, 142.6, 143.6, 144.3, 156.8, 157.2, 160.9; MS (ESI+): m/z: 469 [M + 
H]+. 
 
N-(4-(3,5-dimethoxyphenethyl)phenyl)-6-methoxy-1,2,3,4-tetrahydroacridin-9-
amine (92) 
Coupling of compound 99 (0.170 g, 0.66 mmol) and 
100 (0.168 g, 0.66 mmol) with phenol (0.248 g, 4 equiv) 
was performed according to the general procedure 
described above. Yellow solid, 0.140 g, 0.29 mmol, 
45% yield. 1H NMR (CDCl3, 400 MHz) δ: 1.86-1.90 
(m, 2H), 1.94-1.98 (m, 2H), 2.75 (t, J= 6.2 Hz, 2H), 3.14 (t, J= 6.4 Hz, 2H), 3.83 (s, 
6H), 5.87 (br, 1H, -NH-), 6.38 (t, J= 2Hz, 1H, aromatic), 6.64-6.69 (m, 4H, aromatic), 
6.89 (d, J= 16 Hz, 1H), 7.01 (d, J= 16.4 Hz, 1H), 7.25-7.28 (m, 3H, aromatic), 7.37 (d, 
J= 8.0 Hz, 2H, aromatic), 7.70 (d, J= 8.8 Hz, 1H, aromatic), 7.99 (d, J= 2.0 Hz, 1H, 
aromatic). 13C NMR (CDCl3, 100 MHz) δ: 22.7, 22.8, 25.4, 34.2, 55.5, 99.8, 104.6, 
117.0, 121.5, 123.8, 125.0, 126.1, 126.8, 127.9, 128.7, 130.4, 134.8, 139.8, 143.4, 
144.0, 148.1, 161.15, 161.22; MS (ESI+): m/z: 471 [M + H]+. 
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(E)-N-(4-(3,5-dimethoxystyryl)phenyl)-1,2,3,4-tetrahydroacridin-9-amine (93) 
Coupling of compound 99 (0.176 g, 0.69 mmol) and 101 
(0.100 g, 0.46 mmol) with phenol (0.390 g, 9 equiv) was 
performed according to the general procedure described 
above. Orange solid, 0.093 g, 0.21 mmol, 46% yield. 1H 
NMR (CDCl3, 400 MHz) δ: 1.86-1.90 (m, 2H), 1.95-1.99 
(m, 2H), 2.76 (t, J= 6.2 Hz, 2H), 3.17 (t, J= 6.6 Hz, 2H), 
3.82 (s, 6H), 5.93 (br, 1H, -NH-), 6.37 (s, 1H, aromatic), 6.63-6.70 (m, 4H, aromatic), 
6.89 (d, J= 16.4 Hz, 1H), 7.01 (d, J= 16Hz, 1H), 7.33-7.38 (m, 3H, aromatic), 7.61 (t, J= 
7.6 Hz, 1H, aromatic), 7.79 (d, J= 8.8 Hz, 1H, aromatic), 8.02 (d, J= 8.0 Hz, 1H, 
aromatic). 13C NMR (CDCl3, 100 MHz) δ: 22.8, 23.0, 25.6, 31.0, 34.1, 55.5, 99.8, 
104.5, 110.2, 116.8, 123.2, 125.3, 126.5, 127.8, 128.9, 129.0, 130.1, 139.9, 144.3, 
144.5, 160.2, 161.2; MS (ESI+): m/z: 437 [M + H]+. 
 
(E)-N-(4-(3,5-dimethoxystyryl)phenyl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-
amine (94) 
Coupling of compound 99 (0.268 g, 0.69 mmol) and 102 
(0.174 g, 1.05 mmol) with phenol (0.590 g, 9 equiv) was 
performed according to the general procedure described 
above. Brown solid, 0.106 g, 0.23 mmol, 32% yield. 1H 
NMR (CDCl3, 400 MHz) δ: 1.85 (m, 2H), 1.83-1.87 (m, 
2H), 1.91-1.95 (m, 2H), 2.75 (t, J= 6.2 Hz, 2H), 3.11 (t, J= 6.6 Hz, 2H), 3.68 (s, 3H), 
3.80 (s, 6H), 5.77 (br, 1H, -NH-), 6.35 (t, J= 2.2 Hz, 1H, aromatic), 6.62-6.65 (m, 4H, 
aromatic), 6.86 (d, J= 16.4 Hz, 1H), 6.98 (d, J= 2.8 Hz, 1H, aromatic), 6.99 (d, J= 16.4 
Hz, 1H), 7.24-7.27 (m,1H, aromatic), 7.34 (d, J= 8.4 Hz, 2H, aromatic), 7.89 (d, J= 9.6 
Hz, 1H, aromatic). 13C NMR (CDCl3, 100 MHz) δ: 15.4, 22.9, 23.0, 25.5, 33.8, 55.50, 
55.53, 66.0, 99.8, 101.7, 104.5, 106.9, 116.6, 121.5, 124.1, 126.3, 127.8, 128.9, 129.7, 
130.25, 130.32, 139.9, 144.3, 157.1, 161.2; MS (ESI+): m/z: 467 [M + H]+. 
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5-(4-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)phenethyl)benzene-1,3-diol (91) 
Compound 88 (0.500 g, 1.06 mmol) was dissolved in 
anhydrous DCM (12 mL). The mixture was cooled to -
78 °C and a 1M DCM solution of BBr3 (4.2 mL, 4.2 
mmol, 4 eq) was added dropwise under N2 atmosphere. 
The reaction mixture was stirred at the same 
temperature for 0.5 h and then at rt for 20h. Ice and then 
aqueous NaOH 10% were added and the mixture was extracted with DCM (1x10 mL) 
to remove impurities. The alkaline aqueous phase was acidified with HCl 6N, and a 
yellow precipitate was formed. The precipitate was filtered and washed with water and 
diethyl ether and then purified by flash chromatography (DCM/MeOH 98:2). Yellow 
solid, 0.440 g, 0.98 mmol, 93% yield. 1H NMR (CD3OD, 400 MHz) δ 1.81-1.82 (m, 
2H), 1.90-1.92 (m, 2H), 2.62-2.70 (m, 4H), 2.74-2.78 (m, 2H), 3.02-3.05 (m, 2H), 6.05-
6.09 (m, 3H, aromatic), 6.63-6.64 (d, 2H, aromatic), 6.97-6.99 (d, 2H, aromatic), 7.25-
7.27 (d, 1H, aromatic), δ: 7.78-7.81 (m, 2H, aromatic). 13C NMR (CD3OD, 100 MHz): 
δ: 23.5, 26.5, 33.4, 38.1, 39.2, 101.2, 108.1, 120.4, 121.1, 122.0, 125.3, 126.4, 127.3, 
130.4, 136.6, 137.3, 142.8, 145.3, 146.7, 148.9, 159.3, 160.6; MS (ESI+): m/z: 445 [M + 
H]+. 
 
 (E)-5-(4-((6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino)styryl)benzene-1,3-diol 
(95) 
Compound 92 (0.400 g, 0.85 mmol) was dissolved in 
anhydrous DCM (12 mL). The mixture was cooled to -
78 °C and a 1M DCM solution of BBr3 (3.39 mL, 3.39 
mmol, 4 eq) was added dropwise under N2 atmosphere. 
The reaction mixture was stirred at the same 
temperature for 0.5 h and then at RT for 20 h. Aqueous 
NaOH 10% was added and mixture was extracted with EtOAc (3 x 20 mL). Combined 
organic phases were dried over sodium sulfate and evaporated. Crude product was 
purified by flash chromatography (petroleum ether/EtOAc 50:50). Yellow solid, 0.090 
g, 0.20 mmol, 31% yield. 1H NMR (CD3OD, 400 MHz) δ: 1.80-1.84 (m, 2H), 1.93-1.96 
(m, 2H), 2.71 (t, J= 6.4 Hz, 2H), 3.07 (t, J= 6.4 Hz, 2H), 6.14 (t, J= 2.0 Hz, 1H, 
aromatic), 6.42 (d, J= 2.0 Hz, 2H, aromatic), 6.67 (d, J= 8.4 Hz, 2H, aromatic), 6.81 (d, 
J= 16.4 Hz, 1H), 6.94 (d, J= 16.4 Hz, 1H), 7.29-7.35 (m, 3H, aromatic), 7.84-7.86 (m, 
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2H, aromatic). 13C NMR (CD3OD, 100 MHz) δ: 23.6, 26.7,  34.5, 102.8, 105.9, 118.1, 
122.9, 125.1, 126.6, 126.9, 127.1, 127.5, 128.5, 129.2, 131.4, 135.5, 141.2, 145.6, 
146.4, 148.5, 159.7, 162.6; MS (ESI+): m/z: 443 [M + H]+. 
 
4-(3,5-dimethoxyphenethyl)aniline (98) 
A solution of (E)-1,3-dimethoxy-5-(4-nitrostyryl)benzene 97 
(0.2 g, 0.70 mmol) in EtOAc (20 mL) was reduced on an H-
Cube® flow hydrogenator using a Palladium catalyst 
cartridge 10% Pd/C, with the following conditions: full H2 
mode, T= r.t.; P(H2)= 1 bar; flow rate: 1.0 mL/min. Volatile components were 
evaporated in vacuum to give the crude 4-(3,5-dimethoxyphenethyl)aniline as brown 
oil. 98 was used in the coupling step without further purification. 0.17 g, 0.65 mmol, 
93% yield. 1H NMR (CDCl3, 400 MHz) δ 2.81 (s, 4H), 3.77 (s, 6H), 6.31 (t, J= 2.4Hz, 
1H, aromatic), 6.35 (d, J= 2.4 Hz, 2H, aromatic), 6.63 (d, J= 8.0 Hz, 2H, aromatic), 6.99 
(d, J= 8 Hz, 2H, aromatic). 
 
(E)-4-(3,5-dimethoxystyryl)aniline (99) 
 (E)-1,3-dimethoxy-5-(4-nitrostyryl)benzene 97 (0.2 g, 0.70 
mmol) was dissolved in EtOAc (30 mL). 6 equivalents of 
Tin (II) chloride dehydrate (0.95 g, 4.20 mmol) were added 
and mixture was refluxed for 7h. Than other 2 equivalents 
(0.32 g, 1.42 mmol) were added and the mixture was refluxed for other 5h. Saturated 
aqueous sodium bicarbonate was added to achieve alkalinity. Precipitate was formed. 
The mixture was filtered and the filtrate was extracted with EtOAc (3 x 10mL), than 
evaporated to obtain the product as brown solid. The compound was used in coupling 
step without further purification. 0.17 g, 0.65 mmol, 93% yield. 1H NMR (CDCl3, 400 
MHz) δ: 3.83 (s, 6H), 6.36 (t, J= 2.4 Hz, 1H, aromatic), 6.64 (d, J= 2.4 Hz, 2H, 
aromatic), 6.68 (dd, J= 2.0 Hz, 6.4 Hz, 2H, aromatic), 6.85 (d, J= 16.4 Hz, 1H, 
aromatic), 7.00 (d, J= 16.4, 1H, aromatic), 7.33 (dd, J= 2.0 Hz, 6.8 Hz, 2H, aromatic). 
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CONCLUDING REMARKS 
The totality of my PhD research has been directed to chemical manipulation of synthetic 
building blocks in order to obtain biologically active molecules, useful as tools both for 
drug discovery and chemical biology. 
 
    The main project (Part I) of my PhD program focused on the synthesis of structural 
analogs of the LDH-A inhibitor galloflavin (GF). Since the poor chemical 
manipulability of GF did not allow an easy access to synthesis of analogs, a structural 
simplification was performed which led to the identification of a natural 
dibenzopyranone, urolithin M6 (UM6). 
An efficient and versatile synthetic procedure to obtain UM6 has been developed and 
preliminary biological test showed it reproduced GF’s behaviour, making it a new hit 
suitable for our investigations. The synthetic route developed for UM6 has been 
exploited for the synthesis of a small library of UM6 structural analogs bearing the 
same dibenzopyranone scaffold or phenanthrene and biphenyl scaffolds, proving to be a 
convenient strategy in term of high yields, short reaction times and versatility. 
Furthermore, a small number of dibenzopyranone and dibenzopyrane derivatives were 
obtained through some of the previously reported procedures for urolithins synthesis. 
Biological evaluation of the new derivatives allowed a SAR assessment for this class of 
compounds. UM6 and the new active compounds are currently under further 
investigations to a deeper knowledge of their glycolytic inhibitor activity. These studies, 
in parallel with docking studies, could allow a further optimization of the active 
compounds toward more potent inhibitors. 
 
    Part II, related to the research activity carried out during the six-month placement 
under the supervision of Professor Angela Russell at Department of Chemistry 
(University of Oxford), focused on the development of small molecules useful as 
chemical tools to investigate pathways involved in neurogenesis and neural stem cell 
(NSC) fate. 
A series of derivatives including alkyne-tagged analogs of the recently discovered 
proneurogenic compound OX02672 have been synthesized for subsequent development 
into fluorescent and affinity probes by “click” conjugation with azide-containing 
reporters. Some of the alkyne-tagged analogs were therefore conjugated with a simple 
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azide and a rhodamine-azide-derivative through click chemistry, proving this strategy 
can be useful for the development of OX02672 into fluorescent probes. With the same 
approach, alkyne-tagged derivatives could be developed also as affinity probes by 
conjugation with biotin-azide-derivative in the click reaction. These probes can be used 
in chemical proteomics and other chemical biology methods to assess the localization in 
NSCs and to identify the target protein(s). This in turn may help to understand the 
mechanism of action of OX02672 and to gain a better knowledge of the signaling 
pathways that control adult neurogenesis. 
 
    Finally, a side project (Part III) was carried out in collaboration with the group of 
Professor Maria Laura Bolognesi. It involved the rational design and synthesis of a new 
series of multi-target-directed ligands (MTDLs) against Alzheimer's disease (AD). 
By using a fusing strategy, a new series of tacrin-resveratrol hybrids have been designed 
and synthesized. New derivatives showed interesting multi-target profile against target 
proteins involved in AD pathogenesis and low toxicity on primary neurons. However, a 
general hepatotoxicity was evident for all the compounds, probably due to the presence 
of tacrin fragment. In this regard, is important to keep in mind that toxicity issues 
should be addressed very early in a drug discovery project. Our findings added new 
layers of information to multi-target drug discovery and may be useful for approaches 
aimed to the development of hybrid compounds. 
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Appendix A  
Experiments performed by Professor Giuseppina Di Stefano’s group 
 
Enzymatic assays on purified human LDH-A 
Purified LDH-A (from human liver) was obtained from Lee Biosolutions (St Louis, 
Missouri, USA). 20 mM stock solutions of compoundwas prepared in DMSO. It was 
added in scalar amounts (0 – 200 µM final concentrations) to a reaction mix containing 
100 mM phosphate buffer pH 7.5, 0.015 U LDH / ml, 1 mM pyruvate and 150 µM 
NADH. For all the determinations (including those without the compounds), DMSO in 
the reaction mix was always kept to 0.6%. The enzymatic activity was measured by 
monitoring NADH oxidation for a period of 3 min. To avoid interference of the 
compounds with the UV reading of NADH oxidation, we adopted the procedure 
reported by Moran7, which measured LDH activity by recording the decrease of NADH 
fluorescence. The assay was performed in 96-well white body plates, using a 
Fluoroskan Ascent FL reader (Labsystems). The concentration of compounds causing 
50% inhibition of LDH activity (IC50) was calculated from the second order polynomial 
regression of the experimental data, using the Prism 5 GraphPad software. 
 
Cell culture conditions 
Raji cells were grown as a suspension culture in RPMI 1640 containing 10% FBS, 100 
U/ml penicillin/streptomycin, 4 mM glutamine and were maintained at a concentration 
of 1-2 x 105 viable cells/ml. All media and supplements were from Sigma. In all 
experiments, inhibitors were added to the culture media in the presence of 0.6% DMSO. 
The same amount of DMSO was always added to the control, untreated cultures. 
 
Effects of  the inhibitors on lactate production 
5 x 105 cells in 1 mL of culture medium were seeded in each well of a 6-well Nunclon 
plate. Scalar amounts of inhibitor (0-200 µM, tested in duplicate) were then added to the 
cultures. Lactate was measured in 3 untreated wells at the start of experiment (baseline 
value) and 3 h after incubation at 37°C. In each well, we simultaneously measured 
released in medium and intracellular lactate: at the end of incubation 100 µl of 100% 
trichloroacetic acid (TCA) solution was added; the cell lysate was collected and the well 
was washed with 1 mL 10% TCA. After centrifugation, lactate in the supernatant was 
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measured according to the method of Barker and Summerson.8 The amount of 
metabolite formed during the 3 h incubation with or without the inhibitor was calculated 
by subtracting the baseline value. The dose of compound causing 50% inhibition of 
lactate production (IC50) was calculated from the second order polynomial regression of 
experimental data, using the Prism 5 GraphPad software. 
 
Effects of the inhibitors on cell growth or viability 
To study the effect of the inhibitor on cell proliferation, 1 x 105 cells were seeded in 24-
multiwell plates and treated for 24 h at 37°C with scalar doses of inhibitors (0-200 µM, 
tested in duplicate). After incubation, cells were counted under a light microscope using 
a Neubauer chamber and their viability was determined by Trypan blue exclusion. The 
cell growth was calculated from the difference between the number of viable cells 
counted at 24 h and that at the beginning of experiment. Data were plotted as cell 
growth vs dose of compound. The dose causing 50% inhibition of cell growth (cell 
growth IC50) was calculated by applying the second order polynomial regression to the 
experimental data.  
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Appendix B  
Experiments performed by Dr. Julie Davies (Oxford University) 
 
Cell culture and in vitro compound screening procedures 
DCX-GFP mice with CD1 background strain were sacrificed at 3-5 days old. NSCs 
from the DG and SVZ, and astrocytes from the cerebral cortex were dissected and 
grown in polyheme coated plates to prevent adherence with neural basal A media 
(Gibco), 1% pen/strep, 1% glutamax and 2% B27 supplement (all Sigma). The NSCs 
were also grown in the presence of EGF and FGF to encourage cell expansion. NSCs 
were incubated until secondary or tertiary neurospheres, at 37 °C and 5% CO2 in a 
humidified incubator.  
384 well plates were treated with poly-ornithine to encourage cell adhesion, left at rt 
overnight and the poly-ornithine extracted from the plate. Plates were then treated with 
laminin for 1 h at 37 °C and the laminin then extracted. The suspended neurospheres 
were removed from the polyheme coated plates, centrifuged at 1200 rpm for 5 min to 
form a pellet of cells and the supernatant media removed before being triturated to 
promote dissociation. The neurospheres were then treated with Accutase® to dissociate 
the cells and form a single cell suspension, and then centrifuged again. The suspension 
was made up in a known volume of media and the cell total counted using a Motics 
AE2000 microscope. Cells were seeded onto the coated 384 plates at 2000 cells/well in 
10μL/well and incubated for 1 h. Compounds were dissolved in DMSO at a 
concentration of 10 mM, serially diluted and 40 μL of a given concentration was added 
to the well to give a final compound concentration of 100, 10, 1, 0.1, 0.01 and 0.001 
μM. Experiments were repeated in both technical and biological triplicate. Plates were 
then incubated for 6 days. Immunocytochemistry was then performed by staining cells 
with GFAP, TUJ1, MAP2 antibodies and DAPI nuclear stain. 5 images of the stained 
cells were taken per well using a Perkin Elmer Operetta microscope and x20 objective, 
and the number DAPI+/TUJI+ cells were counted. The percentage of neurons against 
the total number of DAPI stained cells was calculated. 
The number of neurons in a compound-treated well was compared to that in the 
normalised, negative control of DMSO and the fold change calculated. All-trans retinoic 
acid (ATRA) known to induce neurogenesis in vitro (1) was used as the positive 
control.  ATRA gave a dose dependent increase in the proportion of neurons up to ~2.5-
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fold when compared to the DMSO control. At higher concentrations this effect 
decreased, attributed to increased toxicity.  
 
(1) Maden, M. Retinoic acid in the development, regeneration and maintenance of 
the nervous system. Nat. Rev. Neurosci. 8, 755-765 (2007) 
 
In Vivo experiments with OX02672 
Quantification BrdU/NeuN in the anterior and posterior dentate gyrus (1 week 
treatment) 
• 3 breeding pairs (♂ Transgenics and  ♀ wild types) 
• 8 other J20s 
• 25mg/kg via oral gavage TID for 7 days with BrdU in the drinking water 
• 14 day resting period and then perfused 
• BrdU (Proliferating cells), NeuN (Mature neurons) and DAPI (Nuclear dye) 
• Hippocampal staining 
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Abbreviations and acronyms 
ABP: Activity-based probe 
ABPP: Activity-based protein profiling 
AKT: Protein kinase B 
COSY: Correlation spectroscopy 
CuAAC: Copper(I)-catalyzed azide-alkyne cycloaddition 
DCM: Dichloromethane 
DCC: N,N'-Dicyclohexylcarbodiimide 
DIBAL: Diisobutylaluminum hydride 
DCE: 1,2-Dichloroethane 
DCM: Dichloromethane 
DG: Dentate gyrus 
DIPEA: N,N-Diisopropylethylamine 
DMA: N,N-Dimethylacetamide 
DMAP: Dimethylaminopyridine 
DME: 1,2-Dimethoxyethane 
DMF: N,N-dimethylformamide 
DMSO: Dimethyl sulfoxide 
EA: Ellagic acid 
ECAT: Endogenous cell activation therapy  
EDC: N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
GA: Gallic acid 
GF: Galloflavin 
GSK-3β: Glycogen synthase kinase 3 beta 
HIF: Hypoxia-inducible factor 
HMBC: Heteronuclear multiple-bond correlation spectroscopy 
HPLC: High performance liquid chromatography 
HRMS: High-resolution mass spectrometry 
HSQC: Heteronuclear single quantum coherence spectroscopy 
HTS: High-throughput screening 
IR: Infrared 
LDH-A: Lactate dehydrogenase isoform A (tetramer) 
LiHMDS: Lithium bis(trimethylsilyl)amide 
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mTOR: Mammalian target of rapamycin 
NAD+: Nicotinamide adenine dinucleotide (oxidized form) 
NADH: Nicotinamide adenine dinucleotide (reduced form) 
NBS: N-bromosuccinimide 
NSC: Neural stem cell 
NPC: Neural progenitor cell 
NIS: N-Iodosuccinimide 
NMR: Nuclear magnetic resonance 
NOESY: Nuclear Overhauser effect spectroscopy 
PCC: Pyridinium chlorochromate 
PDH: Pyruvate dehydrogenase 
PDK: Pyruvate dehydrogenase kinase 
PI3K: phosphatidylinositol 3-kinase 
PG: Protecting group 
SAR: Structure-activity relationship 
SDS-PAGE: Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
SGZ: Subgranular zone 
SVZ: Subventricular zone 
S-Phos: 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl 
THF: Tetrahydrofuran 
TLC: Thin layer chromatography 
UM6: Urolithin M6 
UM7: Urolithin M7 
Uro-A: Urolithin A 
Uro-B: Urolithin B 
Uro-D: Urolithin D 
Uro-E: Urolthin E 
VS: Virtual screening 
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